CA2520968C - Charged initiator polymers and methods of use - Google Patents
Charged initiator polymers and methods of use Download PDFInfo
- Publication number
- CA2520968C CA2520968C CA2520968A CA2520968A CA2520968C CA 2520968 C CA2520968 C CA 2520968C CA 2520968 A CA2520968 A CA 2520968A CA 2520968 A CA2520968 A CA 2520968A CA 2520968 C CA2520968 C CA 2520968C
- Authority
- CA
- Canada
- Prior art keywords
- initiator
- polymer
- positively
- groups
- initiator polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 328
- 239000003999 initiator Substances 0.000 title claims abstract description 318
- 238000000034 method Methods 0.000 title claims description 94
- 125000002091 cationic group Chemical group 0.000 claims abstract description 103
- 239000000463 material Substances 0.000 claims abstract description 62
- 239000011159 matrix material Substances 0.000 claims abstract description 24
- 239000003505 polymerization initiator Substances 0.000 claims abstract description 24
- 229920002873 Polyethylenimine Polymers 0.000 claims description 28
- 238000006116 polymerization reaction Methods 0.000 claims description 25
- 239000000975 dye Substances 0.000 claims description 18
- -1 phloxime Natural products 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 10
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 6
- 125000005496 phosphonium group Chemical group 0.000 claims description 6
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical group C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 4
- 229930006711 bornane-2,3-dione Natural products 0.000 claims description 4
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims description 4
- 239000004174 erythrosine Substances 0.000 claims description 4
- 229940011411 erythrosine Drugs 0.000 claims description 4
- 235000012732 erythrosine Nutrition 0.000 claims description 4
- UKZQEOHHLOYJLY-UHFFFAOYSA-M ethyl eosin Chemical compound [K+].CCOC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 UKZQEOHHLOYJLY-UHFFFAOYSA-M 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- YYGBVRCTHASBKD-UHFFFAOYSA-M methylene green Chemical compound [Cl-].C1=CC(N(C)C)=C([N+]([O-])=O)C2=[S+]C3=CC(N(C)C)=CC=C3N=C21 YYGBVRCTHASBKD-UHFFFAOYSA-M 0.000 claims description 4
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 229930187593 rose bengal Natural products 0.000 claims description 4
- 229940081623 rose bengal Drugs 0.000 claims description 4
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims description 4
- 229940075420 xanthine Drugs 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 2
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims 2
- 230000005284 excitation Effects 0.000 claims 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 2
- 238000005538 encapsulation Methods 0.000 abstract description 41
- 230000015572 biosynthetic process Effects 0.000 abstract description 23
- 210000004027 cell Anatomy 0.000 description 128
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 39
- 239000000243 solution Substances 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000178 monomer Substances 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 17
- 239000003638 chemical reducing agent Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000370 acceptor Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 12
- 229920001577 copolymer Polymers 0.000 description 12
- 239000000412 dendrimer Substances 0.000 description 12
- 229920000736 dendritic polymer Polymers 0.000 description 12
- 238000012695 Interfacial polymerization Methods 0.000 description 11
- 229940072056 alginate Drugs 0.000 description 11
- 229920000615 alginic acid Polymers 0.000 description 11
- 235000010443 alginic acid Nutrition 0.000 description 11
- 125000003277 amino group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000013047 polymeric layer Substances 0.000 description 8
- 238000010526 radical polymerization reaction Methods 0.000 description 8
- 150000003512 tertiary amines Chemical class 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 229920000768 polyamine Polymers 0.000 description 4
- 229920000656 polylysine Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229920000578 graft copolymer Polymers 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 229920000962 poly(amidoamine) Polymers 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 239000012966 redox initiator Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- RSROEZYGRKHVMN-UHFFFAOYSA-N 2-ethyl-2-(hydroxymethyl)propane-1,3-diol;oxirane Chemical compound C1CO1.CCC(CO)(CO)CO RSROEZYGRKHVMN-UHFFFAOYSA-N 0.000 description 2
- NIXVAPHNPNMUIX-UHFFFAOYSA-N 6-amino-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCN NIXVAPHNPNMUIX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 208000017983 photosensitivity disease Diseases 0.000 description 2
- 231100000434 photosensitization Toxicity 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PWGMGHBDJVKUJJ-UHFFFAOYSA-N 1-[2-(ethenoxymethyl)phenyl]-2-methoxy-2-phenylethanone Chemical compound COC(C(C1=C(C=CC=C1)COC=C)=O)C1=CC=CC=C1 PWGMGHBDJVKUJJ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- XNIOWJUQPMKCIJ-UHFFFAOYSA-N 2-(benzylamino)ethanol Chemical compound OCCNCC1=CC=CC=C1 XNIOWJUQPMKCIJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical group CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- ANHLDZMOXDYFMQ-UHFFFAOYSA-N 2-hydroxythioxanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC(O)=CC=C3SC2=C1 ANHLDZMOXDYFMQ-UHFFFAOYSA-N 0.000 description 1
- PJWWRFATQTVXHA-UHFFFAOYSA-M 3-(cyclohexylamino)propane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-M 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 238000010546 Norrish type I reaction Methods 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 108700020479 Pancreatic hormone Proteins 0.000 description 1
- 208000013612 Parathyroid disease Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000011000 absolute method Methods 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003286 aryl halide group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- LYBKPDDZTNUNNM-UHFFFAOYSA-N isopropylbenzylamine Chemical compound CC(C)NCC1=CC=CC=C1 LYBKPDDZTNUNNM-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical group OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical group CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical compound NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 description 1
- DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010512 small scale reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000005497 tetraalkylphosphonium group Chemical group 0.000 description 1
- OSWMMVUHYHQYCV-UHFFFAOYSA-N tetrabenzylazanium Chemical compound C=1C=CC=CC=1C[N+](CC=1C=CC=CC=1)(CC=1C=CC=CC=1)CC1=CC=CC=C1 OSWMMVUHYHQYCV-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OEIXGLMQZVLOQX-UHFFFAOYSA-N trimethyl-[3-(prop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCNC(=O)C=C OEIXGLMQZVLOQX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/087—Acrylic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
Abstract
Positively-charged initiator polymers having a polymerization initiator group and a cationic portion are provided. The initiator polymers can be used with a polymerizable material for the formation of a polymeric matrix on a surface.
The initiator polymers are particularly useful for cell encapsulation using macromers.
The initiator polymers are particularly useful for cell encapsulation using macromers.
Description
Charged Initiator Polymers and Methods of Use Field of the Invention The current invention relates to compounds useful for forming a polymeric matrix on the surface of a substrate. More specifically, the invention relates to initiator polymers useful for forming a polymeric matrix on the surface of a biological substrate.
Background The use of polymeric material for the encapsulation of cells and tissue offers great potential for the treatment of diseases and other medical indications.
Particularly useful applications involve utilizing polymeric material for encapsulating tissues or cells for transplantation into a patient in order to provide therapy. Although various techniques for encapsulating mammalian cells have been known for a number of decades and have been used in research settings, it is only more recently that cell encapsulation technologies have been applied for the potential treatment of diseases.
Cell encapsulation methods are generally aimed at surrounding a cell or group of cells with a material barrier in order to protect the transplanted encapsulated cells from host immune rejection. The material barrier around the cells ideally allows the cells to remain viable and to function properly in order to provide therapeutic value to the host. In order to perform this function, the material that is used to encapsulate the cells, which typically includes a polymeric compound, should be resistant to biodegradation and should be sufficiently permeable to allow for diffusion of cellular waste products, nutrients, and molecules involved in cellular responses. Preferably the material barrier is not permeable to certain host molecules, such as immunoglobulins and complement factors that could contribute to the destruction of the foreign cells.
Advances in cell encapsulation technologies have been focused on improving the permselectivity, mechanical properties, immune protectivity and biocompatibility of the material barrier that is formed around the cells.
Various micro- and macroencapsulation techniques, including microencapsulation by
Background The use of polymeric material for the encapsulation of cells and tissue offers great potential for the treatment of diseases and other medical indications.
Particularly useful applications involve utilizing polymeric material for encapsulating tissues or cells for transplantation into a patient in order to provide therapy. Although various techniques for encapsulating mammalian cells have been known for a number of decades and have been used in research settings, it is only more recently that cell encapsulation technologies have been applied for the potential treatment of diseases.
Cell encapsulation methods are generally aimed at surrounding a cell or group of cells with a material barrier in order to protect the transplanted encapsulated cells from host immune rejection. The material barrier around the cells ideally allows the cells to remain viable and to function properly in order to provide therapeutic value to the host. In order to perform this function, the material that is used to encapsulate the cells, which typically includes a polymeric compound, should be resistant to biodegradation and should be sufficiently permeable to allow for diffusion of cellular waste products, nutrients, and molecules involved in cellular responses. Preferably the material barrier is not permeable to certain host molecules, such as immunoglobulins and complement factors that could contribute to the destruction of the foreign cells.
Advances in cell encapsulation technologies have been focused on improving the permselectivity, mechanical properties, immune protectivity and biocompatibility of the material barrier that is formed around the cells.
Various micro- and macroencapsulation techniques, including microencapsulation by
- 2 -polyelectrolyte complexation, thennoreversible gelation, interfacial precipitation, interfacial polymerization, and flat sheet and hollow fiber-based macroencapsulation have been studied and are reviewed by Uludag et al. Adv. Drug Deliv. Rev.
42:29-64 (2000).
One commonly used method for the encapsulation of cells is the alginate crosslinking method, which utilizes polyanionic alginate and polycationic polylysine polymers. Encapsulation by the alginate method typically occurs by the crosslinking of alginate via the Ca24- ion and the interaction of polylysine with the alginate molecules. Unfortunately, there are a number of problems associated with this approach to cell encapsulation. Such problems include the swelling of alginate micro capsules due to the presence of Calf in the inner alginate core, insufficient biocompatibility due to guluronic acid content in alginate/polylysine capsules, and insufficient mechanical strength of the alginate coating. Moreover, the process of alginate encapsulation is nonspecific and can result in the formation of microcapsules that do not contain the cells or cell groups intended to be encapsulated or that contain other non-target biological materials. Due to these problems, alternative methods for cell encapsulation have been investigated.
One promising alternative to alginate crosslinking is a method termed interfacial polymerization. Interfacial polymerization has the possibility of offering all of the advantages of the alginate encapsulation method for cellular encapsulation and its therapeutic applications, although there has been little done to investigate its potential. Interfacial polymerization generally involves the formation of a layer of polymerized material, such as synthetic or natural polymerizable polymers, on the surface of a biological substrate. The formation of the layer of polymeric material is generally promoted by the activation of a polymerization initiator, which is deposited on the surface of the biological substrate, in the presence of the polymerizable polymers.
Some polymerization initiators for use in interfacial polymerization methods have been demonstrated in U.S. Patent No. 5,410,016 and U.S. Patent No.
=
5,529,914. These patents describe depositing the polymerization initiator, eosin Y, on a cell membrane and then activating the initiator to promote polymerization of a macromer solution. However, the use of eosin Y, which is a relatively nonpolar,
42:29-64 (2000).
One commonly used method for the encapsulation of cells is the alginate crosslinking method, which utilizes polyanionic alginate and polycationic polylysine polymers. Encapsulation by the alginate method typically occurs by the crosslinking of alginate via the Ca24- ion and the interaction of polylysine with the alginate molecules. Unfortunately, there are a number of problems associated with this approach to cell encapsulation. Such problems include the swelling of alginate micro capsules due to the presence of Calf in the inner alginate core, insufficient biocompatibility due to guluronic acid content in alginate/polylysine capsules, and insufficient mechanical strength of the alginate coating. Moreover, the process of alginate encapsulation is nonspecific and can result in the formation of microcapsules that do not contain the cells or cell groups intended to be encapsulated or that contain other non-target biological materials. Due to these problems, alternative methods for cell encapsulation have been investigated.
One promising alternative to alginate crosslinking is a method termed interfacial polymerization. Interfacial polymerization has the possibility of offering all of the advantages of the alginate encapsulation method for cellular encapsulation and its therapeutic applications, although there has been little done to investigate its potential. Interfacial polymerization generally involves the formation of a layer of polymerized material, such as synthetic or natural polymerizable polymers, on the surface of a biological substrate. The formation of the layer of polymeric material is generally promoted by the activation of a polymerization initiator, which is deposited on the surface of the biological substrate, in the presence of the polymerizable polymers.
Some polymerization initiators for use in interfacial polymerization methods have been demonstrated in U.S. Patent No. 5,410,016 and U.S. Patent No.
=
5,529,914. These patents describe depositing the polymerization initiator, eosin Y, on a cell membrane and then activating the initiator to promote polymerization of a macromer solution. However, the use of eosin Y, which is a relatively nonpolar,
- 3 -low molecular weight light-activated initiator dye, or compounds similar to eosin, presents many disadvantages for interfacial polymerization methods and also presents potential problems to subjects receiving transplanted encapsulated cells.
For example, these dyes and other similar low molecular weight compounds present toxicity problems as they can penetrate into a cell and interfere with norrnal biochemical pathways. If penetrated into the cell, these dyes can cause free radical damage when activated by external sources of energy. Other drawbacks arise if the dye is able to diffuse out of the formed polymeric layer, thereby producing potential toxicity to a host organism. Dyes such as eosin also tend to aggregate in aqueous solution, thereby reducing the efficiency of the encapsulation process and introducing problems with reproducibility. Finally, in view of the limited efficiency of these dyes in initiating sufficient radical chain polymerization, it is often necessary to add one or more monomeric polymerization "accelerators" to the polymerization mixture. These accelerators also tend to be small molecules which are capable of penetrating the cellular membrane and have the potential to be cytotoxic or carcinogenic. Therefore, it is also desirable to minimize the use of these accelerators. In attempts to overcome the above problems, applicants have previously introduced novel interfacial polymerization reagents and techniques (see U.S. Patent Nos. 6,007,833 and 6,410,044).
Despite these teachings, improved initiators for interfacial polymerization methods are desired. The cell surface, to which the polymerization initiator is targeted, is very complex and presents a challenge for the design of initiators that function in a desired manner. For example, the cell surface contains numerous surface proteins, some of which have carbohydrate groups containing charged moieties, such as sulfated proteoglycans and glycosaminoglycans. It is desirable to design initiators that localize to the biological surface but do not affect the physiology of the cell in a negative manner. For example, improved initiators should preferably promote the formation of a polymeric layer on the cell surface in an efficient manner without triggering any detrimental cellular processes, such as signaling pathways that lead to cell death.
For example, these dyes and other similar low molecular weight compounds present toxicity problems as they can penetrate into a cell and interfere with norrnal biochemical pathways. If penetrated into the cell, these dyes can cause free radical damage when activated by external sources of energy. Other drawbacks arise if the dye is able to diffuse out of the formed polymeric layer, thereby producing potential toxicity to a host organism. Dyes such as eosin also tend to aggregate in aqueous solution, thereby reducing the efficiency of the encapsulation process and introducing problems with reproducibility. Finally, in view of the limited efficiency of these dyes in initiating sufficient radical chain polymerization, it is often necessary to add one or more monomeric polymerization "accelerators" to the polymerization mixture. These accelerators also tend to be small molecules which are capable of penetrating the cellular membrane and have the potential to be cytotoxic or carcinogenic. Therefore, it is also desirable to minimize the use of these accelerators. In attempts to overcome the above problems, applicants have previously introduced novel interfacial polymerization reagents and techniques (see U.S. Patent Nos. 6,007,833 and 6,410,044).
Despite these teachings, improved initiators for interfacial polymerization methods are desired. The cell surface, to which the polymerization initiator is targeted, is very complex and presents a challenge for the design of initiators that function in a desired manner. For example, the cell surface contains numerous surface proteins, some of which have carbohydrate groups containing charged moieties, such as sulfated proteoglycans and glycosaminoglycans. It is desirable to design initiators that localize to the biological surface but do not affect the physiology of the cell in a negative manner. For example, improved initiators should preferably promote the formation of a polymeric layer on the cell surface in an efficient manner without triggering any detrimental cellular processes, such as signaling pathways that lead to cell death.
- 4 -Summary of the Invention The current invention provides reagents and methods useful for the formation of a polymeric layer, also referred to herein as a "polymeric matrix" on the surface of a substrate. More specifically, the invention provides a positively-charged polymerization initiator polymer that is useful for the formation of a polymeric layer on negatively charged surfaces. The positively-charged polymerization initiator polymer is particularly useful for encapsulating cells and tissue with biocornpatible polymers.
In one aspect, the positively-charged initiator polymer is used in a method to promote the polymerization of a polymeric material on a biological surface.
The method involves providing a biological surface, which is typically the surface of a cell, group of cells, or a tissue intended to be coated with the polymeric material.
The initiator polymer is then placed in contact with the biological surface.
According to the invention, the initiator polymer includes (i) a polymerization initiator group, and (ii) a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8. The cationic portion can facilitate the solubility of the initiator polymer in an aqueous solution and also allows for the association of the initiator polymer with the cell surface. The cationic portion can be particularly advantageous in embodiments where the initiator polymer contains a plurality of initiator groups, which are typically nonpolar and confer a substantial degree of hydrophobicity to the initiator polymer.
Preferably, the cationic portion also allows for the preparation of initiator polymers that have a weight average molecular weight (Mw) in the low to medium range, contain a plurality of initiator groups, and are soluble in an aqueous solution.
The method of forming a polymeric matrix also involves providing a polymerizable material to the biological surface. The polymerizable material is typically a polymerizable polymer (for example, a macromer) that can be applied before, during or after application of the initiator polymer. Suitable macromers include natural or synthetic polymerizable polymers that preferably provide the formed matrix with an acceptable degree of biocompatibility. After the biological surface has been contacted with the initiator polymer and the macromer, a source of energy is applied to the surface to activate the initiator group, thereby promoting the
In one aspect, the positively-charged initiator polymer is used in a method to promote the polymerization of a polymeric material on a biological surface.
The method involves providing a biological surface, which is typically the surface of a cell, group of cells, or a tissue intended to be coated with the polymeric material.
The initiator polymer is then placed in contact with the biological surface.
According to the invention, the initiator polymer includes (i) a polymerization initiator group, and (ii) a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8. The cationic portion can facilitate the solubility of the initiator polymer in an aqueous solution and also allows for the association of the initiator polymer with the cell surface. The cationic portion can be particularly advantageous in embodiments where the initiator polymer contains a plurality of initiator groups, which are typically nonpolar and confer a substantial degree of hydrophobicity to the initiator polymer.
Preferably, the cationic portion also allows for the preparation of initiator polymers that have a weight average molecular weight (Mw) in the low to medium range, contain a plurality of initiator groups, and are soluble in an aqueous solution.
The method of forming a polymeric matrix also involves providing a polymerizable material to the biological surface. The polymerizable material is typically a polymerizable polymer (for example, a macromer) that can be applied before, during or after application of the initiator polymer. Suitable macromers include natural or synthetic polymerizable polymers that preferably provide the formed matrix with an acceptable degree of biocompatibility. After the biological surface has been contacted with the initiator polymer and the macromer, a source of energy is applied to the surface to activate the initiator group, thereby promoting the
- 5 -polymerization of the macromer on or near the biological surface. According to preferred embodiments, the energy source is provided by long UV wavelengths and more preferably visible light wavelengths. Polymerization can be direct or indirect, wherein indirect methods typically utilize an acceptor or reductant to promote free radical polymerization.
Cells, groups of cells, or tissue can be encapsulated using the positively-charged initiator polymer of the invention. Although the invention is not limited to any particular type of natural or synthetic material as the target surface, the positively-charged initiator polymer is particularly useful as a reagent that promotes the formation of an encapsulating matrix around cells. Encapsulated cells can be transplanted into a subject in order to provide a therapeutic effect. Such applications for the positively-charged initiator polymer include the encapsulation of pancreatic islets for transplantation into a subject having diabetes and in need of therapy.
In another aspect, the invention provides a positively-charged initiator polymer that includes (i) a photoinitiator group selected from the group of visible light-activated dyes, and (ii) a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH
8. The photoinitiator group is coupled to the polymeric backbone of the initiator polymer, and, in preferred embodiments the cationic portion is provided by a cationic group that is also coupled to the polymeric backbone. Suitable photoinitiator groups include visible light-activated dyes such as acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, xanthine dyes, and the like.
Particularly useful initiator polymers include cationic groups that provide the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH 8; more preferably in conditions having a pH at least up to, and including, pH 10, and most preferably in conditions having a pH at least up to, and including, pH 12. Groups conferring these cationic properties can be selected from ternary and quaternary cationic groups such as quaternary ammonium, quaternary phosphonium, and ternary sulfonium groups. Particularly useful initiator polymers have a weight average molecular weight (Mw) in the low to medium molecular weight range, that is, less than about 3.2 X 106 Da. Preferred initiator polymers have
Cells, groups of cells, or tissue can be encapsulated using the positively-charged initiator polymer of the invention. Although the invention is not limited to any particular type of natural or synthetic material as the target surface, the positively-charged initiator polymer is particularly useful as a reagent that promotes the formation of an encapsulating matrix around cells. Encapsulated cells can be transplanted into a subject in order to provide a therapeutic effect. Such applications for the positively-charged initiator polymer include the encapsulation of pancreatic islets for transplantation into a subject having diabetes and in need of therapy.
In another aspect, the invention provides a positively-charged initiator polymer that includes (i) a photoinitiator group selected from the group of visible light-activated dyes, and (ii) a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH
8. The photoinitiator group is coupled to the polymeric backbone of the initiator polymer, and, in preferred embodiments the cationic portion is provided by a cationic group that is also coupled to the polymeric backbone. Suitable photoinitiator groups include visible light-activated dyes such as acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, xanthine dyes, and the like.
Particularly useful initiator polymers include cationic groups that provide the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH 8; more preferably in conditions having a pH at least up to, and including, pH 10, and most preferably in conditions having a pH at least up to, and including, pH 12. Groups conferring these cationic properties can be selected from ternary and quaternary cationic groups such as quaternary ammonium, quaternary phosphonium, and ternary sulfonium groups. Particularly useful initiator polymers have a weight average molecular weight (Mw) in the low to medium molecular weight range, that is, less than about 3.2 X 106 Da. Preferred initiator polymers have
6 a M about 250,000 Da or less, 100,000 Da or less, and 50,000 Da or less. The initiator polymer includes one, and preferably more than one initiator group, and provides initiator activity capable of promoting the polymerization of polymers, (for example macromers) in the presence of a reductant. A particularly preferred initiator polymer includes (i) a polyamine backbone, (ii) a plurality of visible light-activated dyes coupled to the backbone, (iii) a plurality of quaternary ammonium groups coupled to the backbone, and (iv) a M of less than about 3.2 X 106 Da.
The invention also provides a kit for providing a polymeric coating to a surface. The kit includes at least a positively-charged polymerization initiator polymer and a polymerizable material that can be used in conjunction with the initiator polymer. The initiator polymer of the kit includes: (i) a polymerization initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8.
The invention also provides cells, groups of cells, and tissue encapsulated with a polymeric matrix using the positively-charged initiator polymer, as described herein.
Brief Description of the Drawing Fig. 1 illustrates a synthetic scheme for the preparation of a PEG-based macromer, PEG-triacrylate (Compound II).
Detailed Description of the Invention The present invention provides positively-charged initiator polymers, herein also referred to as "initiator polymers", compositions including the initiator polymers, and methods for performing the interfacial polymerization of polymerizable material on or near a surface using these initiator polymers.
"Polymer" refers to a compound having one or more different repeating monomeric units and includes linear polymers and copolymers, branched polymers and copolymers, such as highly branched dendrimer polymers and copolymers, herein referred to as "dendrimers", graft polymers and copolymers, and the like.
"Surface"
broadly refers to any sort of natural or synthetic surfaces. Natural surfaces include "biological surfaces" which broadly refers to the surface of any sort of biological material, such as, for example, the surface of cells, or the surface of a group of cells,
The invention also provides a kit for providing a polymeric coating to a surface. The kit includes at least a positively-charged polymerization initiator polymer and a polymerizable material that can be used in conjunction with the initiator polymer. The initiator polymer of the kit includes: (i) a polymerization initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8.
The invention also provides cells, groups of cells, and tissue encapsulated with a polymeric matrix using the positively-charged initiator polymer, as described herein.
Brief Description of the Drawing Fig. 1 illustrates a synthetic scheme for the preparation of a PEG-based macromer, PEG-triacrylate (Compound II).
Detailed Description of the Invention The present invention provides positively-charged initiator polymers, herein also referred to as "initiator polymers", compositions including the initiator polymers, and methods for performing the interfacial polymerization of polymerizable material on or near a surface using these initiator polymers.
"Polymer" refers to a compound having one or more different repeating monomeric units and includes linear polymers and copolymers, branched polymers and copolymers, such as highly branched dendrimer polymers and copolymers, herein referred to as "dendrimers", graft polymers and copolymers, and the like.
"Surface"
broadly refers to any sort of natural or synthetic surfaces. Natural surfaces include "biological surfaces" which broadly refers to the surface of any sort of biological material, such as, for example, the surface of cells, or the surface of a group of cells,
- 7 -or the surface of a tissue. Synthetic surfaces include any useful man-made materials, such as functionalized and non-functionalized materials made of plastics, ceramic, resins, polysaccharides, silicon, or silica-based materials, glass, metals, films, gels, membranes, nylon, natural fibers such as silk, wool and cotton and polymers.
In one embodiment, the surface has a negative charge and the positively-charged initiator polymer can be associated with this surface via opposite charges.
The initiator polymers are particularly useful for cell encapsulation methods although they can also be used to form a matrix of polymerized material on a biological surface in any sort of ex vivo or in vivo method. Cell encapsulation involves the formation of polymeric layer over all, or a portion of the surface of the cell, group of cells, or tissue. This polymeric layer typically has a certain physical and functional properties, such as thickness, permeability, strength, and protectivity.
Optionally, the initiator polymers can be used to form a matrix of polymerized material on the surface of any type of natural or synthetic material.
According to the invention, positively-charged initiator polymers useful for providing a coating to a surface include at least one polymerization initiator group, and a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH S. The initiator group refers to a portion of the initiator polymer that can specifically accept energy and generate a free radical species, directly or indirectly, and is sufficient to promote free radical polymerization of polymerizable material. The cationic portion provides the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH 8; and, in some embodiments can provide the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH
10, and more preferably up to and including pH of 12. The cationic portion of the initiator polymer can be derived from a positively-charged polymeric backbone, from cationic groups pendent from the backbone, or both. In most embodiments, the cationic property of the initiator polymer is derived from cationic groups pendent from the polymer backbone. "Pendent groups" refer to one or more chemical groups coupled to the polymer backbone anywhere along its length, or chemical groups coupled at either terminus of the backbone, or both.
In one embodiment, the surface has a negative charge and the positively-charged initiator polymer can be associated with this surface via opposite charges.
The initiator polymers are particularly useful for cell encapsulation methods although they can also be used to form a matrix of polymerized material on a biological surface in any sort of ex vivo or in vivo method. Cell encapsulation involves the formation of polymeric layer over all, or a portion of the surface of the cell, group of cells, or tissue. This polymeric layer typically has a certain physical and functional properties, such as thickness, permeability, strength, and protectivity.
Optionally, the initiator polymers can be used to form a matrix of polymerized material on the surface of any type of natural or synthetic material.
According to the invention, positively-charged initiator polymers useful for providing a coating to a surface include at least one polymerization initiator group, and a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH S. The initiator group refers to a portion of the initiator polymer that can specifically accept energy and generate a free radical species, directly or indirectly, and is sufficient to promote free radical polymerization of polymerizable material. The cationic portion provides the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH 8; and, in some embodiments can provide the initiator polymer with a positive charge in conditions having a pH at least up to, and including, pH
10, and more preferably up to and including pH of 12. The cationic portion of the initiator polymer can be derived from a positively-charged polymeric backbone, from cationic groups pendent from the backbone, or both. In most embodiments, the cationic property of the initiator polymer is derived from cationic groups pendent from the polymer backbone. "Pendent groups" refer to one or more chemical groups coupled to the polymer backbone anywhere along its length, or chemical groups coupled at either terminus of the backbone, or both.
- 8 -In one embodiment, the initiator polymer can be used in a step in a method for coating a biological surface, such as a cell encapsulation method. In these methods, the initiator polymer is used in conjunction with a surface to be coated and polymerizable material, such as macromers. In some embodiments the initiator polymer is applied to the cells separately from the macromer component; in other embodiments the initiator polymer and the macromer component are applied together as a polymerizable composition to the cells. Therefore, the invention also provides compositions that include a positively-charged initiator polymer and a macromer component. Compounds useful for cell encapsulation, such as reductants/acceptors and other polymerization enhancing components, for example, stabilizers, viscosity enhancing agents, and co-catalysts, can be introduced into the polymerization method in existing steps, in additional steps, or can be present as a reagent in a polymerizable composition. Therefore, the invention also provides polymerizable compositions and kits for forming a polymer coating on a surface that can include an initiator polymer, a macromer component, a reductant/acceptor, and a viscosity-enhancing agent.
In a more specific embodiment, the invention provides an initiator polymer that includes a visible light-activated photoinitiator group, and a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH
at least up to, and including, pH 8. The visible light-activated photoinitiator group can be selected from the group of visible light activated dyes such as eosin. In another specific embodiment, the invention provides an initiator polymer having a plurality of visible light-activated photoinitiator groups coupled to the polymer backbone, a plurality of ternary or quaternary cationic groups coupled to the polymer backbone, and a 1\4, of less than 3.2 X 106 Da.
As used herein "weight average molecular weight" or 1\4, is an absolute method of measuring molecular weight and is particularly useful for measuring the molecular weight of a polymer (preparation), such as preparations of initiator polymers and macromers. Polymer preparations typically include polymers that individually have minor variations in molecular weight. Polymers are molecules that have a relatively high molecular weight and such minor variations within the polymer preparation do not affect the overall properties of the polymer preparation
In a more specific embodiment, the invention provides an initiator polymer that includes a visible light-activated photoinitiator group, and a cationic portion that provides a positive charge to the initiator polymer in conditions having a pH
at least up to, and including, pH 8. The visible light-activated photoinitiator group can be selected from the group of visible light activated dyes such as eosin. In another specific embodiment, the invention provides an initiator polymer having a plurality of visible light-activated photoinitiator groups coupled to the polymer backbone, a plurality of ternary or quaternary cationic groups coupled to the polymer backbone, and a 1\4, of less than 3.2 X 106 Da.
As used herein "weight average molecular weight" or 1\4, is an absolute method of measuring molecular weight and is particularly useful for measuring the molecular weight of a polymer (preparation), such as preparations of initiator polymers and macromers. Polymer preparations typically include polymers that individually have minor variations in molecular weight. Polymers are molecules that have a relatively high molecular weight and such minor variations within the polymer preparation do not affect the overall properties of the polymer preparation
- 9 -(for example, the characteristics of an initiator polymer preparation). The weight average molecular weight (Mw) can be defined by the following formula:
NMi2 Mw = NiMi wherein N represents the number of moles of a polymer in the sample with a mass of M, and Ei is the sum of all NiMi (species) in a preparation. The Mõ, can be measured using common techniques, such as light scattering or ultracentrifugation.
Discussion of Mw and other terms used to define the molecular weight of polymer preparations can be found in, for example, Allcock, H.R. and Lampe, F.W., Contemporary Polymer Chemistry; pg 271 (1990).
The invention also specifically provides the positively-charged initiator polymer as a component in a group of compounds used for interfacial polymerization methods, and methods for the treatment of particular diseases.
These compounds and methods can be implemented for the encapsulation of cells or tissue, wherein the encapsulated cells or tissue are therapeutically useful. For example, pancreatic islets that are encapsulated using the initiator polymer of the invention can be transplanted to a diabetic patient in need of functional pancreatic tissue.
The positive charge provided by the cationic portion of the initiator polymer can allow the initiator polymer to be configured as a surprisingly effective polymerization initiator, particularly for cell encapsulation methods. In one aspect, the positive charge of the initiator polymer can afford the polymer with a high degree of solubility in an aqueous solution. This high degree of solubility in an aqueous solution can be maintained in embodiments wherein the initiator polymer has a plurality of initiator groups, which are typically nonpolar and confer a substantial degree of hydrophobicity to the initiator polymer per se.
Therefore, the presence of the cationic portion can allow for the preparation of initiator polymers that can include a substantial number of initiator groups and function as polymerization initiators when the initiator groups are activated. This arrangement is particularly advantageous, as it has been discovered initiator polymers having a low to medium M, can be prepared and used in cell encapsulation processes while
NMi2 Mw = NiMi wherein N represents the number of moles of a polymer in the sample with a mass of M, and Ei is the sum of all NiMi (species) in a preparation. The Mõ, can be measured using common techniques, such as light scattering or ultracentrifugation.
Discussion of Mw and other terms used to define the molecular weight of polymer preparations can be found in, for example, Allcock, H.R. and Lampe, F.W., Contemporary Polymer Chemistry; pg 271 (1990).
The invention also specifically provides the positively-charged initiator polymer as a component in a group of compounds used for interfacial polymerization methods, and methods for the treatment of particular diseases.
These compounds and methods can be implemented for the encapsulation of cells or tissue, wherein the encapsulated cells or tissue are therapeutically useful. For example, pancreatic islets that are encapsulated using the initiator polymer of the invention can be transplanted to a diabetic patient in need of functional pancreatic tissue.
The positive charge provided by the cationic portion of the initiator polymer can allow the initiator polymer to be configured as a surprisingly effective polymerization initiator, particularly for cell encapsulation methods. In one aspect, the positive charge of the initiator polymer can afford the polymer with a high degree of solubility in an aqueous solution. This high degree of solubility in an aqueous solution can be maintained in embodiments wherein the initiator polymer has a plurality of initiator groups, which are typically nonpolar and confer a substantial degree of hydrophobicity to the initiator polymer per se.
Therefore, the presence of the cationic portion can allow for the preparation of initiator polymers that can include a substantial number of initiator groups and function as polymerization initiators when the initiator groups are activated. This arrangement is particularly advantageous, as it has been discovered initiator polymers having a low to medium M, can be prepared and used in cell encapsulation processes while
- 10 -maintaining a high level of cell viability. Therefore, according to the invention, the cationic portion of the initiator polymer allows for the preparation of initiator polymers that are soluble in an aqueous solution and that have a high degree of "initiator potential", referring to the ability of a particular compound to initiate the polymerization of polymerizable material. In this regard it is not necessary to increase the size of the initiator polymer to improve solubility in an aqueous solution.
In another aspect, the positive charge of the initiator polymer can also allow for its interaction with negatively charged surfaces, for example, negatively charged surfaces of biological material. Cell surface proteins that bear anionic charged groups typically impart a negative charge over the cell surface. Surface molecules such as glycosaminoglycans and sulfated proteoglycans contribute to the charged surface of a cell. However, other biological materials that have a negatively charged surface can also be suitable as surfaces that can associate with the initiator polymer of the invention. Therefore, the cationic portion of the initiator polymer provides a convenient way of localizing the initiator polymer to a target anionic surface, particularly a cell surface, during cell encapsulation process.
According to the invention, the initiator polymer includes one or more initiator groups that are coupled to the backbone of the initiator polymer.
The initiator groups of the initiator polymer are able to promote free radical polymerization of polymerizable material, such as macromers, when the initiator groups are activated by an external source of energy. Activated initiator groups can cause free radical polymerization of the polymerizable material either directly or indirectly. Indirect methods typically include the transfer of energy from the activated initiator to an acceptor or reductant, a chemical species that can form a free radical and can act to cause polymerization of the polymerizable material. In direct methods the initiator group provides the free radical itself.
According to the invention, the initiator polymer can be localized to a negatively charged surface, such as the surface of a biological material. Upon activation of the initiator groups, polymerizable material that is in proximity to the initiator polymer polymerizes, leading to the formation of a layer of polymeric
In another aspect, the positive charge of the initiator polymer can also allow for its interaction with negatively charged surfaces, for example, negatively charged surfaces of biological material. Cell surface proteins that bear anionic charged groups typically impart a negative charge over the cell surface. Surface molecules such as glycosaminoglycans and sulfated proteoglycans contribute to the charged surface of a cell. However, other biological materials that have a negatively charged surface can also be suitable as surfaces that can associate with the initiator polymer of the invention. Therefore, the cationic portion of the initiator polymer provides a convenient way of localizing the initiator polymer to a target anionic surface, particularly a cell surface, during cell encapsulation process.
According to the invention, the initiator polymer includes one or more initiator groups that are coupled to the backbone of the initiator polymer.
The initiator groups of the initiator polymer are able to promote free radical polymerization of polymerizable material, such as macromers, when the initiator groups are activated by an external source of energy. Activated initiator groups can cause free radical polymerization of the polymerizable material either directly or indirectly. Indirect methods typically include the transfer of energy from the activated initiator to an acceptor or reductant, a chemical species that can form a free radical and can act to cause polymerization of the polymerizable material. In direct methods the initiator group provides the free radical itself.
According to the invention, the initiator polymer can be localized to a negatively charged surface, such as the surface of a biological material. Upon activation of the initiator groups, polymerizable material that is in proximity to the initiator polymer polymerizes, leading to the formation of a layer of polymeric
- 11 -material, or a matrix, on the surface. This type of polymerization is typically referred to as interfacial polymerization.
The initiator polymer can include light-activated photoinitiator groups, thermally activated initiator groups, chemically activated initiator groups, or combinations thereof. Suitable thermally activated initiator groups include 4,4' azobis(4-cyanopentanoic) acid and 2,2-azobis[2-(2-imidazolin-2-y1) propane]
dihydrochloride or other thermally activated initiators provided these initiators can be incorporated into an initiator polymer. Chemically activated initiation is often referred to as redox initiation, redox catalysis, or redox activation. In general, combinations of organic and inorganic oxidizers, and organic and inorganic reducing agents are used to generate radicals for polymerization. A description of redox initiation can be found in Principles of Polymermization, 2nd Edition, Odian G., John Wiley and Sons, pgs 201-204, (1981). Redox initiators that are not damaging to biological systems are preferably used. Photoinitiator groups and thermally activated initiator groups that utilize energy that is not damaging to biological systems are preferably used. In one embodiment, photoinitiator groups having long wavelength UV and visible light-activated frequencies are coupled to the backbone of the initiator polymer. In a preferred embodiment, visible light-activated photoinitiators are coupled to the polymer backbone.
Photoinitiation can occur by various mechanisms, including Norrish type I
reactions, intra- or intermolecular hydrogen abstraction reactions, and photosensitization reactions utilizing photoreducible or photo-oxidizable dyes. The latter two types of reactions are commonly used with an energy transfer acceptor or a reductant, which can be, for example, a tertiary amine. Such tertiary amines can be incorporated into the polymeric backbone of the macromer. In a preferred embodiment, the initiator polymer includes one or more initiator groups that allow for intra- or intermolecular hydrogen abstraction reactions or photosensitization reactions utilizing photoreducible or photo-oxidizable dyes when activated.
Useful energy transfer acceptors or reductants for use with these types of initiators include, but are not limited to, tertiary amines such as triethanolamine, triethylamine, N-methyl diethanolamine, N,N-dimethyl benzylamine, tetramethyl ethylenediamine;
The initiator polymer can include light-activated photoinitiator groups, thermally activated initiator groups, chemically activated initiator groups, or combinations thereof. Suitable thermally activated initiator groups include 4,4' azobis(4-cyanopentanoic) acid and 2,2-azobis[2-(2-imidazolin-2-y1) propane]
dihydrochloride or other thermally activated initiators provided these initiators can be incorporated into an initiator polymer. Chemically activated initiation is often referred to as redox initiation, redox catalysis, or redox activation. In general, combinations of organic and inorganic oxidizers, and organic and inorganic reducing agents are used to generate radicals for polymerization. A description of redox initiation can be found in Principles of Polymermization, 2nd Edition, Odian G., John Wiley and Sons, pgs 201-204, (1981). Redox initiators that are not damaging to biological systems are preferably used. Photoinitiator groups and thermally activated initiator groups that utilize energy that is not damaging to biological systems are preferably used. In one embodiment, photoinitiator groups having long wavelength UV and visible light-activated frequencies are coupled to the backbone of the initiator polymer. In a preferred embodiment, visible light-activated photoinitiators are coupled to the polymer backbone.
Photoinitiation can occur by various mechanisms, including Norrish type I
reactions, intra- or intermolecular hydrogen abstraction reactions, and photosensitization reactions utilizing photoreducible or photo-oxidizable dyes. The latter two types of reactions are commonly used with an energy transfer acceptor or a reductant, which can be, for example, a tertiary amine. Such tertiary amines can be incorporated into the polymeric backbone of the macromer. In a preferred embodiment, the initiator polymer includes one or more initiator groups that allow for intra- or intermolecular hydrogen abstraction reactions or photosensitization reactions utilizing photoreducible or photo-oxidizable dyes when activated.
Useful energy transfer acceptors or reductants for use with these types of initiators include, but are not limited to, tertiary amines such as triethanolamine, triethylamine, N-methyl diethanolamine, N,N-dimethyl benzylamine, tetramethyl ethylenediamine;
- 12 -secondary amines such as dibenzyl amine, N-benzyl ethanolamine, N-isopropyl benzylamine; and primary amines such as ethanolamine, lysine, and ornithine.
In one embodiment, photoinitiator groups having an absorbance of 350 nm and greater are used. More preferably, photoinitiator groups having an absorbance of 500 nm and greater are used. Suitable photoinitiator groups include light-activated initiator groups, such as long-wave ultra violet (LWUV) light-activatable molecules and visible light activatable molecules. Suitable long-wave ultra violet (LWUV) light-activatable molecules include, but are not limited to, ((9-oxo-2-thioxanthany1)-oxy)acetic acid, 2-hydroxy thioxanthone, and vinyloxymethylbenzoin methyl ether. Suitable visible light activatable photoinitiator groups include, but are not limited to, acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, and xanthine dyes.
One common feature on these visible light activatable photoinitiator groups, and photoinitiator groups in general, is that of having a nonpolar portion.
Due to the presence of this nonpolar portion, these photoinitiator groups generally have a low solubility in aqueous solutions. When these photoinitiator groups are coupled to another molecule, such as an initiator polymer, the photoinitiator groups can confer nonpolar characteristics to the polymer and can generally reduce its solubility in an aqueous solution.
The initiator polymer contains a number of initiator groups in an amount sufficient to promote free radical polymerization of polymerizable material on the surface of a substrate, such as the surface of a biological material. The initiator polymer contains at least one and more typically a plurality of initiator groups. In some cases, the initiator polymer is highly loaded with initiator groups and can provide a high level of polymerization initiator activity. This arrangement may be desirable in methods or compositions that include macromers that do not readily polymerize to form a polymeric layer. Accordingly, the invention provides positively-charged initiator polymers that are highly loaded with initiator groups.
Therefore, in one embodiment, the initiator polymer includes at least one initiator group. In more preferred embodiments the initiator polymer includes 5 or more initiator groups, and in even more preferred embodiments the initiator polymer
In one embodiment, photoinitiator groups having an absorbance of 350 nm and greater are used. More preferably, photoinitiator groups having an absorbance of 500 nm and greater are used. Suitable photoinitiator groups include light-activated initiator groups, such as long-wave ultra violet (LWUV) light-activatable molecules and visible light activatable molecules. Suitable long-wave ultra violet (LWUV) light-activatable molecules include, but are not limited to, ((9-oxo-2-thioxanthany1)-oxy)acetic acid, 2-hydroxy thioxanthone, and vinyloxymethylbenzoin methyl ether. Suitable visible light activatable photoinitiator groups include, but are not limited to, acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, and xanthine dyes.
One common feature on these visible light activatable photoinitiator groups, and photoinitiator groups in general, is that of having a nonpolar portion.
Due to the presence of this nonpolar portion, these photoinitiator groups generally have a low solubility in aqueous solutions. When these photoinitiator groups are coupled to another molecule, such as an initiator polymer, the photoinitiator groups can confer nonpolar characteristics to the polymer and can generally reduce its solubility in an aqueous solution.
The initiator polymer contains a number of initiator groups in an amount sufficient to promote free radical polymerization of polymerizable material on the surface of a substrate, such as the surface of a biological material. The initiator polymer contains at least one and more typically a plurality of initiator groups. In some cases, the initiator polymer is highly loaded with initiator groups and can provide a high level of polymerization initiator activity. This arrangement may be desirable in methods or compositions that include macromers that do not readily polymerize to form a polymeric layer. Accordingly, the invention provides positively-charged initiator polymers that are highly loaded with initiator groups.
Therefore, in one embodiment, the initiator polymer includes at least one initiator group. In more preferred embodiments the initiator polymer includes 5 or more initiator groups, and in even more preferred embodiments the initiator polymer
- 13 -includes about 10 or more initiator groups. In even more preferred embodiments, the initiator polymer has a Mw of 3.2 X 106 Da or less, most preferably 250,000 Da or less, and includes 5 or more initiator groups, and more preferably about 10 or more initiator groups. The initiator groups can be pendent along the polymer backbone at any position and can be spaced in a random or ordered manner.
The initiator group can be coupled to the initiator polymer using any suitable method. In one method, for example, polymerizable monomers having initiator groups can be synthesized and subsequently used in a polymerization reaction to create an initiator polymer with pendent initiator groups. Synthesis of initiator-derivatized monomers can be readily accomplished using standard chemical reactions. For example, an acid chloride analog of a photoinitiator group, such as a light-activated dye, can be reacted with an ethylenically unsaturated amine-containing monomer to form an initiator-derivatized monomer. In another method of preparing the initiator polymer, preformed polymers having reactive groups are reacted with initiator groups to attach the initiator groups to the preformed polymer.
For example, an isothiocyanate or an acid chloride analog of a photoinitiator can be reacted with a polymer containing pendent amine groups thereby forming an initiator polymer bearing pendent initiator groups. Other synthetic schemes known to those of skilled in the art can be employed to prepare the initiator polymer. These schemes are contemplated but will not be discussed in further detail.
In preferred embodiments the initiator polymer includes a plurality of initiator groups that are nonpolar. The presence of a plurality of nonpolar initiator groups can confer substantial hydrophobic properties to the initiator polymer.
Accordingly, this substantial hydrophobic property can be counter balanced by providing the initiator polymer with a cationic portion, which is discussed in greater detail below.
The positive charge of the cationic portion of the initiator polymer can be contributed by the backbone of the initiator polymer, by positively-charged groups pendent from the backbone, or both. In one embodiment, the initiator polymer has a plurality of cationic groups pendent from the backbone of the initiator polymer;
preferably the cationic groups are provided by ternary or quaternary cationic =
moieties, such as quaternary amine groups. In another embodiment the polymeric
The initiator group can be coupled to the initiator polymer using any suitable method. In one method, for example, polymerizable monomers having initiator groups can be synthesized and subsequently used in a polymerization reaction to create an initiator polymer with pendent initiator groups. Synthesis of initiator-derivatized monomers can be readily accomplished using standard chemical reactions. For example, an acid chloride analog of a photoinitiator group, such as a light-activated dye, can be reacted with an ethylenically unsaturated amine-containing monomer to form an initiator-derivatized monomer. In another method of preparing the initiator polymer, preformed polymers having reactive groups are reacted with initiator groups to attach the initiator groups to the preformed polymer.
For example, an isothiocyanate or an acid chloride analog of a photoinitiator can be reacted with a polymer containing pendent amine groups thereby forming an initiator polymer bearing pendent initiator groups. Other synthetic schemes known to those of skilled in the art can be employed to prepare the initiator polymer. These schemes are contemplated but will not be discussed in further detail.
In preferred embodiments the initiator polymer includes a plurality of initiator groups that are nonpolar. The presence of a plurality of nonpolar initiator groups can confer substantial hydrophobic properties to the initiator polymer.
Accordingly, this substantial hydrophobic property can be counter balanced by providing the initiator polymer with a cationic portion, which is discussed in greater detail below.
The positive charge of the cationic portion of the initiator polymer can be contributed by the backbone of the initiator polymer, by positively-charged groups pendent from the backbone, or both. In one embodiment, the initiator polymer has a plurality of cationic groups pendent from the backbone of the initiator polymer;
preferably the cationic groups are provided by ternary or quaternary cationic =
moieties, such as quaternary amine groups. In another embodiment the polymeric
- 14 -backbone contains nitrogen and can be, for example, a polymeric imine.
According to preferred embodiment of the invention, the cationic portion can provide the initiator polymer with a positive charge allowing for solubility in an aqueous solution and/or the ability to interact with a negatively charged surface.
The cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH 8 is particularly advantageous in embodiments wherein the initiator polymer includes a plurality of nonpolar initiator groups. The hydrophobic properties conferred by the nonpolar initiator groups can be counteracted by the presence of a cationic portion present on the initiator polymer, which can improve the solubility of the initiator polymer in aqueous solutions. According to the invention, the cationic portion is arranged to allow the initiator polymer to be soluble in aqueous solution and is also arranged to allow the initiator polymer to interact with a negatively charged surface, such as the surface of a cell. The cationic portion is arranged to provide a positive charge to the initiator polymer in environments having a pH at least up to, and including pH
8;
and in some aspects the cationic portion is arranged to provide a positive charge to the initiator polymer in environments having a pH at least up to, and including, pH
10, and more preferably in environments having a pH at least up to, and including, pH 12.
In order to determine whether the initiator polymer maintains a positive charge in conditions having a pH of up to, and including, pH 8, any one of a number of tests can be performed. A suitable test for a positively-charged initiator polymer can generally involve preparing a buffered solution having a pH of 8, or higher than 8, adding the initiator polymer to the buffered solution, placing the polymer solution in contact with a material that provides a negative charge, and then determining whether the initiator polymer interacts with the negatively charged material.
For example, an initiator polymer can be added to a solution that has been adjusted to a pH of 8 or greater with a suitable high-pH buffer such as tris(hydroxymethyl)aminomethane, ammonium bicarbonate, or 3-(cyclohexylamino)-1-propanesulfonate; the polymer mixture can then be applied to an anionic exchange matrix (for example, Q-Sepharose; Amersham Biosciences Corp., Piscataway, NJ); the column can then be washed with the high-pH buffer;
According to preferred embodiment of the invention, the cationic portion can provide the initiator polymer with a positive charge allowing for solubility in an aqueous solution and/or the ability to interact with a negatively charged surface.
The cationic portion that provides a positive charge to the initiator polymer in conditions having a pH at least up to, and including, pH 8 is particularly advantageous in embodiments wherein the initiator polymer includes a plurality of nonpolar initiator groups. The hydrophobic properties conferred by the nonpolar initiator groups can be counteracted by the presence of a cationic portion present on the initiator polymer, which can improve the solubility of the initiator polymer in aqueous solutions. According to the invention, the cationic portion is arranged to allow the initiator polymer to be soluble in aqueous solution and is also arranged to allow the initiator polymer to interact with a negatively charged surface, such as the surface of a cell. The cationic portion is arranged to provide a positive charge to the initiator polymer in environments having a pH at least up to, and including pH
8;
and in some aspects the cationic portion is arranged to provide a positive charge to the initiator polymer in environments having a pH at least up to, and including, pH
10, and more preferably in environments having a pH at least up to, and including, pH 12.
In order to determine whether the initiator polymer maintains a positive charge in conditions having a pH of up to, and including, pH 8, any one of a number of tests can be performed. A suitable test for a positively-charged initiator polymer can generally involve preparing a buffered solution having a pH of 8, or higher than 8, adding the initiator polymer to the buffered solution, placing the polymer solution in contact with a material that provides a negative charge, and then determining whether the initiator polymer interacts with the negatively charged material.
For example, an initiator polymer can be added to a solution that has been adjusted to a pH of 8 or greater with a suitable high-pH buffer such as tris(hydroxymethyl)aminomethane, ammonium bicarbonate, or 3-(cyclohexylamino)-1-propanesulfonate; the polymer mixture can then be applied to an anionic exchange matrix (for example, Q-Sepharose; Amersham Biosciences Corp., Piscataway, NJ); the column can then be washed with the high-pH buffer;
- 15 -finally, the column can be eluted with a salt-containing buffer (such as 0.5 M
NaC1) to dissociate the initiator polymer, if bound. If the initiator polymer maintains a positive charge in the selected buffer conditions, it will be present and detectable by spectroscopy in the eluate. Other commonly used analytical methods useful for determining the charge of the initiator polymer in a solution having a pH of 8 or more are contemplated and will not be discussed further.
In some embodiments, the initiator polymer has a polymeric backbone that is coupled to at least one and more typically a plurality of cationic groups. The polymer backbone, which generally refers to the polymer chain without addition of any initiator group or cationic group, typically includes carbon and preferably one or more atoms selected from nitrogen, oxygen, and sulfur. The backbone can include carbon-carbon linkages and, in some preferred embodiments, can also include one or more of amide, amine, ester, ether, ketone, peptide, or sulfide linkages, or combinations thereof. Examples of suitable polymer backbones include polyesters, polycarbonates, polyamides, polyethers (such as polyoxyethylene), polysulfones, polyurethanes, or copolymers containing any combination of the representative monomer groups.
The polymeric backbone can include reactive groups useful for the coupling of cationic groups to form the initiator polymer. Suitable reactive groups include acid (or acyl) halide groups, alcohol groups, aldehyde groups, alkyl and aryl halide groups, amine groups, carboxyl groups, and the like. These pendent reactive groups can be used for the coupling the initiator group and, in some embodiments, for the coupling of the cationic groups to the polymeric backbone. These chemical groups can be present either on a preformed polymer or on monomers used to create the positively-charged initiator polymer. Examples of polymers having suitable reactive or charged side group include polymers, and in particular dendrimers, having reactive amine groups such as polylysine, polyornithine, polyethylenimine, and polyamidoamine.
In one embodiment of the invention, the backbone of the initiator polymer provides an overall positive charge and contributes to the cationic portion.
An example of this type of polymeric backbone includes polymers having imine linkages, such as polyimines that also include primary, secondary, or tertiary amine
NaC1) to dissociate the initiator polymer, if bound. If the initiator polymer maintains a positive charge in the selected buffer conditions, it will be present and detectable by spectroscopy in the eluate. Other commonly used analytical methods useful for determining the charge of the initiator polymer in a solution having a pH of 8 or more are contemplated and will not be discussed further.
In some embodiments, the initiator polymer has a polymeric backbone that is coupled to at least one and more typically a plurality of cationic groups. The polymer backbone, which generally refers to the polymer chain without addition of any initiator group or cationic group, typically includes carbon and preferably one or more atoms selected from nitrogen, oxygen, and sulfur. The backbone can include carbon-carbon linkages and, in some preferred embodiments, can also include one or more of amide, amine, ester, ether, ketone, peptide, or sulfide linkages, or combinations thereof. Examples of suitable polymer backbones include polyesters, polycarbonates, polyamides, polyethers (such as polyoxyethylene), polysulfones, polyurethanes, or copolymers containing any combination of the representative monomer groups.
The polymeric backbone can include reactive groups useful for the coupling of cationic groups to form the initiator polymer. Suitable reactive groups include acid (or acyl) halide groups, alcohol groups, aldehyde groups, alkyl and aryl halide groups, amine groups, carboxyl groups, and the like. These pendent reactive groups can be used for the coupling the initiator group and, in some embodiments, for the coupling of the cationic groups to the polymeric backbone. These chemical groups can be present either on a preformed polymer or on monomers used to create the positively-charged initiator polymer. Examples of polymers having suitable reactive or charged side group include polymers, and in particular dendrimers, having reactive amine groups such as polylysine, polyornithine, polyethylenimine, and polyamidoamine.
In one embodiment of the invention, the backbone of the initiator polymer provides an overall positive charge and contributes to the cationic portion.
An example of this type of polymeric backbone includes polymers having imine linkages, such as polyimines that also include primary, secondary, or tertiary amine
- 16 -groups. Use of these types of polymers in the synthesis of the initiator polymer are preferred as they can provide a highly derivatizable preformed polymer backbone to which a plurality of cationic groups and initiator groups can be coupled.
Polyamines that are particularly suitable as a starting polymer for the synthesis of the initiator polymer include polyethylenimine, polypropylenimine, and the like, and polyamine polymers or copolymers, and in particular dendrimers, formed from monomers such as the following amine functional monomers: 2-aminomethylmethacrylate, 3-(aminopropy1)-methacrylamide, and diallylamine. Suitable polyamines are commercially available, for example, LupasolTM PS (polyethylenimine; BASF, New Jersey).
In preferred embodiments of the invention, the backbone of the initiator polymer is coupled to one or more cationic groups. Preferred cationic groups have a stable positive charge and include ternary and quaternary cationic groups.
Preferred cationic groups include quaternary ammonium, quaternary phosphonium, and ternary sulfonium. These types of cationic groups can provide the initiator polymer with a positive charge in a wide range of pH conditions, particularly in higher pH
conditions wherein other cationic groups can become deprotonated and lose their positive charge. The positive charge on these initiator polymers is maintained at least in conditions having a pH up to, and including, pH 8; and in some aspects in conditions having a pH up to, and including, pH 10, and in some aspects in conditions having a pH up to, and including, pH 12.
As indicated, preferred cationic groups include quaternary ammonium, ternary sulfonium, and quaternary phosphonium groups. These groups can be provided in, for example, alkylated or alkoxylated forms having, for example, in the range of 1-6 carbons on each chain. Examples include, but are not limited to tetraalkylammonium, tetraalkoxyammonium, trialkylsulfonium, trialkoxysulfonium, tetraalkylphosphonium, and tetraalkoxyphosphonium cations. Specific examples include tetramethylammonium, tetrapropylammonium, tetrabenzylammonium and the like.
The cationic groups can be spaced in a random or ordered pattern along the length of the polymer backbone or can be present primarily on one end of the
Polyamines that are particularly suitable as a starting polymer for the synthesis of the initiator polymer include polyethylenimine, polypropylenimine, and the like, and polyamine polymers or copolymers, and in particular dendrimers, formed from monomers such as the following amine functional monomers: 2-aminomethylmethacrylate, 3-(aminopropy1)-methacrylamide, and diallylamine. Suitable polyamines are commercially available, for example, LupasolTM PS (polyethylenimine; BASF, New Jersey).
In preferred embodiments of the invention, the backbone of the initiator polymer is coupled to one or more cationic groups. Preferred cationic groups have a stable positive charge and include ternary and quaternary cationic groups.
Preferred cationic groups include quaternary ammonium, quaternary phosphonium, and ternary sulfonium. These types of cationic groups can provide the initiator polymer with a positive charge in a wide range of pH conditions, particularly in higher pH
conditions wherein other cationic groups can become deprotonated and lose their positive charge. The positive charge on these initiator polymers is maintained at least in conditions having a pH up to, and including, pH 8; and in some aspects in conditions having a pH up to, and including, pH 10, and in some aspects in conditions having a pH up to, and including, pH 12.
As indicated, preferred cationic groups include quaternary ammonium, ternary sulfonium, and quaternary phosphonium groups. These groups can be provided in, for example, alkylated or alkoxylated forms having, for example, in the range of 1-6 carbons on each chain. Examples include, but are not limited to tetraalkylammonium, tetraalkoxyammonium, trialkylsulfonium, trialkoxysulfonium, tetraalkylphosphonium, and tetraalkoxyphosphonium cations. Specific examples include tetramethylammonium, tetrapropylammonium, tetrabenzylammonium and the like.
The cationic groups can be spaced in a random or ordered pattern along the length of the polymer backbone or can be present primarily on one end of the
- 17 -polymer backbone if desired. The initiator polymer can also include different combinations of cationic groups if desired.
The number of cationic groups pendent on the polymer backbone can be arranged to provide a functional initiator polymer. The function of the initiator polymer can include its solubility in an aqueous solution, its ability to associate with a surface, and its potency as a polymerization initiator. In one aspect, the cationic groups are present in an amount sufficient to solubilize the initiator polymer in an aqueous solution. In another aspect the cationic groups are present in an amount sufficient to allow for the interaction of the initiator polymer with a biological surface. According to the invention, the initiator polymer has at least one monomeric unit that is coupled to a cationic group; more preferably the initiator polymer has about 20% or more of its monomeric units coupled to cationic groups, and most preferably the initiator polymer has about 50% or more of its monomeric units coupled to cationic groups. When a plurality of nonpolar initiator groups are present, the initiator polymer can be arranged with a cationic portion that provides sufficient solubility and that can also be localized to a cell surface. This can be achieved by preparing an initiator polymer that has a defined ratio of initiator groups to cationic groups. Therefore, in one embodiment of the invention, the ratio of cationic groups:initiator groups on the initiator polymer is at least 1:1. In a more preferred embodiment this cationic group:initiator group ratio is at least 2.5:1, and most preferred embodiment ratio is at least 5:1.
In a preferred embodiment, the invention provides an initiator polymer having a positively-charged backbone and a plurality of quaternary amine groups pendent from the positively-charged backbone. The hydrophilic backbone can be a polymeric imine backbone and can have a plurality of quaternary amine groups pendent from the amine-containing backbone. In this embodiment, the presence of the quaternary amine groups allows the initiator polymer to retain a positive charge despite any fluctuations in the pH of the solution, and maintain the solubility of the initiator polymer in solution.
An initiator polymer having an initiator group and a cationic group can be prepared a variety of ways. For example, the initiator group and the cationic group can be attached to a "preformed" polymer or a copolymer that is reactive with the
The number of cationic groups pendent on the polymer backbone can be arranged to provide a functional initiator polymer. The function of the initiator polymer can include its solubility in an aqueous solution, its ability to associate with a surface, and its potency as a polymerization initiator. In one aspect, the cationic groups are present in an amount sufficient to solubilize the initiator polymer in an aqueous solution. In another aspect the cationic groups are present in an amount sufficient to allow for the interaction of the initiator polymer with a biological surface. According to the invention, the initiator polymer has at least one monomeric unit that is coupled to a cationic group; more preferably the initiator polymer has about 20% or more of its monomeric units coupled to cationic groups, and most preferably the initiator polymer has about 50% or more of its monomeric units coupled to cationic groups. When a plurality of nonpolar initiator groups are present, the initiator polymer can be arranged with a cationic portion that provides sufficient solubility and that can also be localized to a cell surface. This can be achieved by preparing an initiator polymer that has a defined ratio of initiator groups to cationic groups. Therefore, in one embodiment of the invention, the ratio of cationic groups:initiator groups on the initiator polymer is at least 1:1. In a more preferred embodiment this cationic group:initiator group ratio is at least 2.5:1, and most preferred embodiment ratio is at least 5:1.
In a preferred embodiment, the invention provides an initiator polymer having a positively-charged backbone and a plurality of quaternary amine groups pendent from the positively-charged backbone. The hydrophilic backbone can be a polymeric imine backbone and can have a plurality of quaternary amine groups pendent from the amine-containing backbone. In this embodiment, the presence of the quaternary amine groups allows the initiator polymer to retain a positive charge despite any fluctuations in the pH of the solution, and maintain the solubility of the initiator polymer in solution.
An initiator polymer having an initiator group and a cationic group can be prepared a variety of ways. For example, the initiator group and the cationic group can be attached to a "preformed" polymer or a copolymer that is reactive with the
- 18 -initiator and cationic groups. The preformed polymer or copolymer can be obtained from a commercial source or be synthesized from the polymerization of a desired monomer or combination of different monomers. In one example of preparing the initiator polymer, the initiator groups and the cationic groups are reacted with and attached, for example, by covalent bonding, to chemical groups pendent from the backbone of the polymer or copolymer. Such attachments of the initiator groups and the cationic groups can be achieved by, for example, substitution or addition reactions.
In one preferred embodiment of the invention, the initiator polymer is prepared using a highly derivatizable preformed polymer as the polymer backbone.
Preferred polymers contain a high number of reactive (derivatizable) groups, such as primary amine groups, relative to the molecular weight of the polymer.
Suitable polymers and copolymers include amine-containing polymeric units such as polyimines, for example, polyethylenimine. Use of these types of polymers or copolymers as backbones for the initiator polymer allows for the preparation of low and medium molecular weight initiator polymers that can be highly loaded with initiator groups and cationic groups.
In another method of preparing the initiator polymer, polymers having primary, secondary, tertiary amines, or combinations thereof, can be quaternized, resulting in the formation of charged quaternary amine groups on the polymer.
For example, amines can be successively alkylated, by, for example, alkyl halides, to provide a quaternary amine via the Menshutkin reaction. In another useful method of synthesizing the initiator polymer, polymers having tertiary amines can be reacted with a photoinitiator derivatized with a benzyl halide, for example. This reaction allows for the coupling of the photoinitiator to the polymer and at the same time converting the tertiary amine group to a charged quaternary amine group.
In yet another method of preparing the initiator polymer, monomers having initiator groups and monomers having cationic groups are first prepared. These initiator and cationic group-containing monomers are then co-polymerized to create an initiator polymer coupled to both initiator and cationic groups. In some embodiments an individual monomer having both an initiator group and a cationic group can be used to prepare the initiator polymer. Optionally, other monomers that
In one preferred embodiment of the invention, the initiator polymer is prepared using a highly derivatizable preformed polymer as the polymer backbone.
Preferred polymers contain a high number of reactive (derivatizable) groups, such as primary amine groups, relative to the molecular weight of the polymer.
Suitable polymers and copolymers include amine-containing polymeric units such as polyimines, for example, polyethylenimine. Use of these types of polymers or copolymers as backbones for the initiator polymer allows for the preparation of low and medium molecular weight initiator polymers that can be highly loaded with initiator groups and cationic groups.
In another method of preparing the initiator polymer, polymers having primary, secondary, tertiary amines, or combinations thereof, can be quaternized, resulting in the formation of charged quaternary amine groups on the polymer.
For example, amines can be successively alkylated, by, for example, alkyl halides, to provide a quaternary amine via the Menshutkin reaction. In another useful method of synthesizing the initiator polymer, polymers having tertiary amines can be reacted with a photoinitiator derivatized with a benzyl halide, for example. This reaction allows for the coupling of the photoinitiator to the polymer and at the same time converting the tertiary amine group to a charged quaternary amine group.
In yet another method of preparing the initiator polymer, monomers having initiator groups and monomers having cationic groups are first prepared. These initiator and cationic group-containing monomers are then co-polymerized to create an initiator polymer coupled to both initiator and cationic groups. In some embodiments an individual monomer having both an initiator group and a cationic group can be used to prepare the initiator polymer. Optionally, other monomers that
- 19 -are not coupled to either an initiator or a cationic group can be polymerized with the cationic and the initiator-coupled monomers to create the initiator polymer.
Methods of preparing the initiator polymer are exemplified below. Other standard methods known to those of skill in the art to prepare the initiator polymer are contemplated and will not be discussed further.
In one embodiment, the initiator polymer of the current invention is generally of a size sufficient to allow for its association with a biological surface and promote the polymerization of macromers on the biological surface upon its activation. In one preferred embodiment of the invention, low and medium molecular weight initiator polymers are used in cell encapsulation processes.
Low and medium molecular weight initiator polymers are referred to as having My, of less than 3.2 X 106 Da, while high molecular weight polymers are referred to as having a Mw of 3.2 X 106 Da and greater.
Therefore, in one preferred embodiment, the invention provides initiator polymers having a (i) a polymerization initiator group, (ii) a cationic portion that provides a positive charge to the polymer in conditions at least up to pH 8, and (iii) a M, of less than 3.2 X 106 Da. In more preferred embodiments the initiator polymer has a M, of about 250,000 Da or less, 100,000 Da or less, and 50,000 Da or less. In another preferred embodiment, the initiator polymers have a Mw in the range from 3400 to about 250,000 Da, more preferably in the range from 8500 to about 250,000 Da, even more preferably in the range from 8500 to about 100,000 Da, and most preferably in the range from 8500 to about 50,000 Da. In another embodiment, the initiator polymer is up to about 1000 monomeric units, and typically in the range of about 25 to about 500 monomeric units.
The initiator polymer typically promotes the polymerization of polymerizable material, such as macromers, on a surface, thereby forming a matrix of polymeric material on the biological surface. The polymerizable material can be any sort of compound, including monomers and polymers having one or more polymerizable groups. Polymerizable groups are portions of the polymerizable compounds that are able to propagate free radical polymerization, such as carbon-carbon double bonds. Preferred polymerizable groups are found in polymerizable compounds having vinyl or acrylate groups. More specific polymerizable portions
Methods of preparing the initiator polymer are exemplified below. Other standard methods known to those of skill in the art to prepare the initiator polymer are contemplated and will not be discussed further.
In one embodiment, the initiator polymer of the current invention is generally of a size sufficient to allow for its association with a biological surface and promote the polymerization of macromers on the biological surface upon its activation. In one preferred embodiment of the invention, low and medium molecular weight initiator polymers are used in cell encapsulation processes.
Low and medium molecular weight initiator polymers are referred to as having My, of less than 3.2 X 106 Da, while high molecular weight polymers are referred to as having a Mw of 3.2 X 106 Da and greater.
Therefore, in one preferred embodiment, the invention provides initiator polymers having a (i) a polymerization initiator group, (ii) a cationic portion that provides a positive charge to the polymer in conditions at least up to pH 8, and (iii) a M, of less than 3.2 X 106 Da. In more preferred embodiments the initiator polymer has a M, of about 250,000 Da or less, 100,000 Da or less, and 50,000 Da or less. In another preferred embodiment, the initiator polymers have a Mw in the range from 3400 to about 250,000 Da, more preferably in the range from 8500 to about 250,000 Da, even more preferably in the range from 8500 to about 100,000 Da, and most preferably in the range from 8500 to about 50,000 Da. In another embodiment, the initiator polymer is up to about 1000 monomeric units, and typically in the range of about 25 to about 500 monomeric units.
The initiator polymer typically promotes the polymerization of polymerizable material, such as macromers, on a surface, thereby forming a matrix of polymeric material on the biological surface. The polymerizable material can be any sort of compound, including monomers and polymers having one or more polymerizable groups. Polymerizable groups are portions of the polymerizable compounds that are able to propagate free radical polymerization, such as carbon-carbon double bonds. Preferred polymerizable groups are found in polymerizable compounds having vinyl or acrylate groups. More specific polymerizable portions
- 20 -include acrylate groups, methacrylate groups, ethacrylate groups, 2-phenyl acrylate groups, acrylamide groups, methacrylamide groups, itaconate groups, and styrene groups. Preferred materials for the encapsulation of cellular material are biocompabible polyraerizable polymers (also referred to as macromers). Such macromers can be straight chain or branched polymers or copolymers, or graft copolymers. Synthetic polymeric macromers, polysaccharide macromers, and protein macromers suitable for use with the initiator polymer of the current invention are described in U.S. Patent No. 5,573,934 (Hubbell et al.).
Preferred macromers include, but are not limited to, polymerizable poly(vinylpyrrolidone) (PVP), poly(ethylene glycol) (PEG), poly(ethylene oxide) poly(ethyloxazoline), poly(propylene oxide), polyacrylamide (PAA), poly(vinyl alcohol) (PVA), copolymers thereof, and the like. In particular, PEG and PAA
are more preferred macromers. These types of macromers are typically soluble in water and are more stable in vivo as compared to biodegradable polymers.
In some cases it may be desirable to use naturally occurring or synthetic macromers as the polymerizable material. Suitable macromers include naturally occurring polymers such as polysaccharides, examples of which include, but are not limited to, hyaluronic acid (HA), starch, dextran, heparin, and chitosan; and proteins (and other polyamino acids), examples of which. include, but are not limited to, gelatin, collagen, fibronectin, lArniniti, albumin and active peptides thereof. In order to make these naturally occurring or synthetic macromers polymerizable, polymerizable groups can be incorporated into a polymer using standard thermochernical reactions. For example, polymerizable groups can be added to collagen via reaction of amine containing lysine residues with acryloyl chloride.
These reactions result in collagen containing polymerizable moieties.
Similarly, when synthesizing a macromer, monomers containing reactive groups can be incorporated into the synthetic scheme. For example, hydroxyethylmethacrylate (HEMA) OT aminopropylmethacrylamide (APMA) can be copolymerized with N-vinylpyrrolidone or acrylamide yielding a water-soluble polymer with pendent hydroxyl or amine groups. These pendent groups can subsequently be reacted with acvyloyl chloride or glycidyl acrylate to form water-soluble polymers with pendent
Preferred macromers include, but are not limited to, polymerizable poly(vinylpyrrolidone) (PVP), poly(ethylene glycol) (PEG), poly(ethylene oxide) poly(ethyloxazoline), poly(propylene oxide), polyacrylamide (PAA), poly(vinyl alcohol) (PVA), copolymers thereof, and the like. In particular, PEG and PAA
are more preferred macromers. These types of macromers are typically soluble in water and are more stable in vivo as compared to biodegradable polymers.
In some cases it may be desirable to use naturally occurring or synthetic macromers as the polymerizable material. Suitable macromers include naturally occurring polymers such as polysaccharides, examples of which include, but are not limited to, hyaluronic acid (HA), starch, dextran, heparin, and chitosan; and proteins (and other polyamino acids), examples of which. include, but are not limited to, gelatin, collagen, fibronectin, lArniniti, albumin and active peptides thereof. In order to make these naturally occurring or synthetic macromers polymerizable, polymerizable groups can be incorporated into a polymer using standard thermochernical reactions. For example, polymerizable groups can be added to collagen via reaction of amine containing lysine residues with acryloyl chloride.
These reactions result in collagen containing polymerizable moieties.
Similarly, when synthesizing a macromer, monomers containing reactive groups can be incorporated into the synthetic scheme. For example, hydroxyethylmethacrylate (HEMA) OT aminopropylmethacrylamide (APMA) can be copolymerized with N-vinylpyrrolidone or acrylamide yielding a water-soluble polymer with pendent hydroxyl or amine groups. These pendent groups can subsequently be reacted with acvyloyl chloride or glycidyl acrylate to form water-soluble polymers with pendent
- 21 -polymerizable groups, Suitable synthetic polymers include hydrophilic monomers containing degradable segments as described in U.S. Patent No. 5,410,016.
In another aspect, the invention provides a polymerizable composition that includes a positively-charged initiator polymer and a macromer. The polymerizable composition can also include other compounds useful in cell encapsulation methods such as reductant/acceptors and viscosity-enhancing agents. Suitable viscosity-enhancing agents include, for example, polyethylene glycols (PEGs), and glycerol.
Therefore, in one embodiment, the invention provides a polymerizable composition that includes: (i) an initiator polymer having at least one polymerization initiator group, and a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8 and (ii) a macromer. In a more specific embodiment the invention provides a polymerizable composition that includes: (i) a photoinitiator group selected from the group of visible light-activated dyes, and (ii) a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8.
As previously indicated, the initiator polymer of the invention is typically used with macromers and, in some cases, a reductant/acceptor in a method to provide a coating to a biological surface. The reagents are particularly suitable for cell encapsulation processes.
Cells or tissue to be encapsulated can be obtained directly from an organism, such as a mammal. Alternatively cells can be obtained fioin a cell culture.
The cells intended for encapsulation can be transformed or otherwise modified. Specific types of cells and tissue that can be encapsulated and used for the treatment of diseases are discussed below. "Cells" refers to individual membrane-bound biological units that can be present as part of a tissue or organ, or can function independently as micro-organisms. "Tissue" refers to a biological mass that includes groups of similar cells, and also typically includes extracellular material that is associated with the cells.
Cells, or tissue in particular, can be subject to treatment prior to the encapsulation process. For example, tissue can be treated with enzymatic or other suitable reagents, such as trypsin, hyaluronidase, or collagenase, to obtain individual cells or cell groups of a suitable size for the encapsulation process. Alternatively, tissue can
In another aspect, the invention provides a polymerizable composition that includes a positively-charged initiator polymer and a macromer. The polymerizable composition can also include other compounds useful in cell encapsulation methods such as reductant/acceptors and viscosity-enhancing agents. Suitable viscosity-enhancing agents include, for example, polyethylene glycols (PEGs), and glycerol.
Therefore, in one embodiment, the invention provides a polymerizable composition that includes: (i) an initiator polymer having at least one polymerization initiator group, and a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8 and (ii) a macromer. In a more specific embodiment the invention provides a polymerizable composition that includes: (i) a photoinitiator group selected from the group of visible light-activated dyes, and (ii) a cationic portion that provides a positive charge to the polymer in conditions having a pH at least up to, and including, pH 8.
As previously indicated, the initiator polymer of the invention is typically used with macromers and, in some cases, a reductant/acceptor in a method to provide a coating to a biological surface. The reagents are particularly suitable for cell encapsulation processes.
Cells or tissue to be encapsulated can be obtained directly from an organism, such as a mammal. Alternatively cells can be obtained fioin a cell culture.
The cells intended for encapsulation can be transformed or otherwise modified. Specific types of cells and tissue that can be encapsulated and used for the treatment of diseases are discussed below. "Cells" refers to individual membrane-bound biological units that can be present as part of a tissue or organ, or can function independently as micro-organisms. "Tissue" refers to a biological mass that includes groups of similar cells, and also typically includes extracellular material that is associated with the cells.
Cells, or tissue in particular, can be subject to treatment prior to the encapsulation process. For example, tissue can be treated with enzymatic or other suitable reagents, such as trypsin, hyaluronidase, or collagenase, to obtain individual cells or cell groups of a suitable size for the encapsulation process. Alternatively, tissue can
- 22 -be subject to mechanical processes in order to prepare suitable cellular starting material. Prior to the encapsulation process, cells can also be treated with drugs, prodrugs, hormones, or the like, or can be cultured to provide cells that display a desired expression pattern or have certain morphological features. Technical references that provide detailed instructions for the preparation of cells or tissue and the treatment of prepared cells or tissue are available and can be found in, for example, in Pollard, J. W. and Walker, J. M. Ed., Basic Cell Culture Protocols (1997). Alternatively, cells or tissue suitable for encapsulation and intended for use with the positively-charged initiator of the invention can be commercially obtained.
For example, viable human liver preparations such as microsomes and hepatocytes, and viable human pancreatic preparations, such as pancreatic islets can be obtained from commercial sources such as CellzDirect, Inc. (Tucson, AZ).
With information available in technical literature, one can utilize the positively-charged initiator polymer in methods for coating a surface, and in particular, in the novel and inventive methods provided herein, for encapsulating cells and tissue. For example, the teaching of Cruise, et al., Cell Transplantation 8:293 (1999), can provide a basis for the cell encapsulation methods using the positively-charged polymerization initiator of the invention. Cells or tissue suitable for the encapsulation process, prepared as indicated above or obtained from a commercial source, can be suspended in a suitable media, such as a biocompatible buffered aqueous media, such as, for example Roswell Park Memorial Institute (RPMI) media. Other reagents can be added to this solution, such as animal serum;
proteins such as albumin; oxidants; reductants; vitamins; minerals; growth factors;
or other components that can have an impact on the viability and function of the cells or tissues as desired.
The positively-charged initiator polymer can be added to this solution before or after contacting the cells or tissue with the solution. The initiator polymer can be brought into contact with the cells in an amount that is sufficient to facilitate formation of a matrix around the cells or tissue. In one embodiment, the concentration of the initiator polymer is from 0.001 to 0.5 wt%. In yet another embodiment, the concentration of the initiator polymer is from 0.1 to 0.25 wt%. In one embodiment the initiator polymer is brought in contact with the cells for a
For example, viable human liver preparations such as microsomes and hepatocytes, and viable human pancreatic preparations, such as pancreatic islets can be obtained from commercial sources such as CellzDirect, Inc. (Tucson, AZ).
With information available in technical literature, one can utilize the positively-charged initiator polymer in methods for coating a surface, and in particular, in the novel and inventive methods provided herein, for encapsulating cells and tissue. For example, the teaching of Cruise, et al., Cell Transplantation 8:293 (1999), can provide a basis for the cell encapsulation methods using the positively-charged polymerization initiator of the invention. Cells or tissue suitable for the encapsulation process, prepared as indicated above or obtained from a commercial source, can be suspended in a suitable media, such as a biocompatible buffered aqueous media, such as, for example Roswell Park Memorial Institute (RPMI) media. Other reagents can be added to this solution, such as animal serum;
proteins such as albumin; oxidants; reductants; vitamins; minerals; growth factors;
or other components that can have an impact on the viability and function of the cells or tissues as desired.
The positively-charged initiator polymer can be added to this solution before or after contacting the cells or tissue with the solution. The initiator polymer can be brought into contact with the cells in an amount that is sufficient to facilitate formation of a matrix around the cells or tissue. In one embodiment, the concentration of the initiator polymer is from 0.001 to 0.5 wt%. In yet another embodiment, the concentration of the initiator polymer is from 0.1 to 0.25 wt%. In one embodiment the initiator polymer is brought in contact with the cells for a
- 23 -period of time that is sufficient for the initiator polymer to associate with the surface of the cells. Optionally, a washing step can be performed. This washing step can be used, for example, to remove excess, unbound initiator or other material in contact with the cells. After the initiator polymer is brought in contact with the cells or tissue, the polymerizable material, such as macromers, can be brought in contact with the cells. In another embodiment, the initiator polymer is brought into contact with the cells or tissue together with the polymerizable material. In yet another embodiment the polymerizable material is brought into contact with the cells prior to bringing the initiator polymer into contact with the cells.
The polymerizable material (for example, macromers) can be brought into contact with the cell or tissue in an amount that allows formation of a matrix of a desired thickness. A concentration of macromer in solution useful for cell encapsulation can be in the range of 5 ¨ 50 wt%, and more preferably in the range of 10 ¨ 30 wt%. In some embodiments, the polymerizable material can be placed in contact with the cells for a period of time prior to activating the positively-charged initiator polymer.
Other reagents can be brought in contact with the cells or tissue during the encapsulation process. As previously mentioned, such reagents include acceptors or reductants, such as tertiary amines (for example, triethanolamine) that can form a free radical and cause free radical polymerization of the polymerizable material.
Suitable acceptors or reductants are known in the art and are commercially available.
These acceptors or reductants are typically used in indirect polymerization methods wherein the initiator group transfers energy to the acceptors or reductants to promote free radical polymerization of the polymerizable material. Reagents such as viscosity-enhancing reagents can also be used in the method of the invention.
Viscosity-enhancing reagents can improve the process of polymerization.
Suitable acceptors or reductants are known in the art and are commercially available.
One of skill in the art can determine suitable amounts of any of these additional reagents for performing the encapsulation process.
After the reagents necessary to promote formation of a matrix are brought in contact with the surface to be coated, a source of energy, such as a thermal or electromagnetic energy sufficient to activate the initiator group, is applied to initiate
The polymerizable material (for example, macromers) can be brought into contact with the cell or tissue in an amount that allows formation of a matrix of a desired thickness. A concentration of macromer in solution useful for cell encapsulation can be in the range of 5 ¨ 50 wt%, and more preferably in the range of 10 ¨ 30 wt%. In some embodiments, the polymerizable material can be placed in contact with the cells for a period of time prior to activating the positively-charged initiator polymer.
Other reagents can be brought in contact with the cells or tissue during the encapsulation process. As previously mentioned, such reagents include acceptors or reductants, such as tertiary amines (for example, triethanolamine) that can form a free radical and cause free radical polymerization of the polymerizable material.
Suitable acceptors or reductants are known in the art and are commercially available.
These acceptors or reductants are typically used in indirect polymerization methods wherein the initiator group transfers energy to the acceptors or reductants to promote free radical polymerization of the polymerizable material. Reagents such as viscosity-enhancing reagents can also be used in the method of the invention.
Viscosity-enhancing reagents can improve the process of polymerization.
Suitable acceptors or reductants are known in the art and are commercially available.
One of skill in the art can determine suitable amounts of any of these additional reagents for performing the encapsulation process.
After the reagents necessary to promote formation of a matrix are brought in contact with the surface to be coated, a source of energy, such as a thermal or electromagnetic energy sufficient to activate the initiator group, is applied to initiate
- 24 -polymerization of the polymerizable material. Long-wave ultra violet (LW'UV) and visible wavelengths in range of 350 nm to 900 nm are preferred and can be supplied by lamps and laser light sources. Lamps or laser light sources that can provide these wavelengths of light are commercially available and can be obtained from, for example, EFOS, Inc. (Mississauga, Ontario, Canada). A particularly suitable wavelength for use with the preferred initiator polymers of the invention is about 520 nm. The time and temperature of the reaction are maintained to provide a desired coating. For example, the cells or tissue in contact with the initiator polymer and macromer can be treated with light for a period in the range of seconds to minutes. The polymerization reaction can be terminated by removing the light source. The encapsulated cells or tissue can then be subject to further treatment if desired. For example, it may be desirable to concentrate the encapsulated material, for example, by centrifugation, prior to introducing the encapsulated material into a subject.
As indicated, a number of technical references that provide detailed procedures for encapsulating cells are available and can provide a framework for which the positively-charged initiator polymer can be used. Therefore, using the available information, one can perform surface coating of a material, more specifically, the encapsulation of cellular material and tissue using the positively-charged initiator polymer and reagents described herein or in other references.
According to the invention, the polymerization initiator can be used to promote the formation of a matrix of polymerized material on a biological surface.
Polymerization using the polymerization initiator can be performed in vivo by applying a polymerization initiator and polymerizable material, either together or separately, to a subject in either invasive or noninvasive procedures. Other particularly useful applications involve the ex vivo encapsulation of cells or tissue.
In this application cells or tissue can be obtained from a suitable source, encapsulated with a matrix of polymeric material using a composition including the initiator polymer described herein, and then introduced into a subject in need of the encapsulated cells or tissue. This type of ex vivo encapsulation and transplantation procedure is advantageous as it can provide a matrix coating affording the transplanted cells protection from host immune rejection yet allowing the
As indicated, a number of technical references that provide detailed procedures for encapsulating cells are available and can provide a framework for which the positively-charged initiator polymer can be used. Therefore, using the available information, one can perform surface coating of a material, more specifically, the encapsulation of cellular material and tissue using the positively-charged initiator polymer and reagents described herein or in other references.
According to the invention, the polymerization initiator can be used to promote the formation of a matrix of polymerized material on a biological surface.
Polymerization using the polymerization initiator can be performed in vivo by applying a polymerization initiator and polymerizable material, either together or separately, to a subject in either invasive or noninvasive procedures. Other particularly useful applications involve the ex vivo encapsulation of cells or tissue.
In this application cells or tissue can be obtained from a suitable source, encapsulated with a matrix of polymeric material using a composition including the initiator polymer described herein, and then introduced into a subject in need of the encapsulated cells or tissue. This type of ex vivo encapsulation and transplantation procedure is advantageous as it can provide a matrix coating affording the transplanted cells protection from host immune rejection yet allowing the
-25 -encapsulated cells to provide a therapeutic value to the host. In some cases, after receiving the transplanted encapsulated cells, the subject can be administered a pharmaceutical agent that can penetrate the polymeric layer that encapsulates the cells and can provoke a cellular response, which is of therapeutic value to the subject.
In one aspect of the invention, the initiator polymer is used to encapsulate cells or tissue from glands and organs of the endocrine system, which include cells from the pituitary gland; cells from the adrenal gland; cells from the thyroid/parathyroid glands; cells from the pancreatic islets, such as beta cells, alpha cells, delta cells, and pancreatic polypeptide (PP) cells; cells from the liver; and cells from reproductive glands such as the testis and ovary. Endocrine cells can be removed from a donor individual and encapsulated with polymeric material using the initiator polymer as described herein.
Encapsulated endocrine cells can be transplanted to an individual having any of the following conditions or needs: a pituitary disorder and in need of growth hormone (GH), adrenocorticotropic hormone (ACTH), follicle stimulating hormone (FSH), leutinizing hormone (LH), thyroid stimulating hormone (TSH), oxytocin, or antidiuretic hormone (ADH); an adrenal disorder and in need of mineral corticoids (for example, aldosterone) glucocorticoids (for example, cortisol), androgenic steroids, or catecholamines such as epinephrine or norepinephrine; a thyroid or parathyroid disorder and in need of thyroxin, calcitonin, or parathyroid hormone (PTH); a pancreatic disorder such as diabetes and in need of insulin, glucagon, somatostatin, or pancreatic polypeptide; a liver disorder and in need of bile or plasma proteins, including clotting factors; a reproductive gland disorder and in need of male hormones such as testosterone or female hormones such as estrogen.
Other types of cells that can be encapsulated include immature and mature cells from the cardiovascular, respiratory, renal, nervous, muscular, and skeletal systems. In some aspects cells that have been transformed or genetically modified can be encapsulated and transplanted into a host. For example, cells that have been transformed or modified to produce a therapeutically useful compound, such as a peptide hormone or an enzyme can be encapsulated and introduced into an.
individual.
In one aspect of the invention, the initiator polymer is used to encapsulate cells or tissue from glands and organs of the endocrine system, which include cells from the pituitary gland; cells from the adrenal gland; cells from the thyroid/parathyroid glands; cells from the pancreatic islets, such as beta cells, alpha cells, delta cells, and pancreatic polypeptide (PP) cells; cells from the liver; and cells from reproductive glands such as the testis and ovary. Endocrine cells can be removed from a donor individual and encapsulated with polymeric material using the initiator polymer as described herein.
Encapsulated endocrine cells can be transplanted to an individual having any of the following conditions or needs: a pituitary disorder and in need of growth hormone (GH), adrenocorticotropic hormone (ACTH), follicle stimulating hormone (FSH), leutinizing hormone (LH), thyroid stimulating hormone (TSH), oxytocin, or antidiuretic hormone (ADH); an adrenal disorder and in need of mineral corticoids (for example, aldosterone) glucocorticoids (for example, cortisol), androgenic steroids, or catecholamines such as epinephrine or norepinephrine; a thyroid or parathyroid disorder and in need of thyroxin, calcitonin, or parathyroid hormone (PTH); a pancreatic disorder such as diabetes and in need of insulin, glucagon, somatostatin, or pancreatic polypeptide; a liver disorder and in need of bile or plasma proteins, including clotting factors; a reproductive gland disorder and in need of male hormones such as testosterone or female hormones such as estrogen.
Other types of cells that can be encapsulated include immature and mature cells from the cardiovascular, respiratory, renal, nervous, muscular, and skeletal systems. In some aspects cells that have been transformed or genetically modified can be encapsulated and transplanted into a host. For example, cells that have been transformed or modified to produce a therapeutically useful compound, such as a peptide hormone or an enzyme can be encapsulated and introduced into an.
individual.
-26 -The initiator polymer and polyrnerizable material can also be used in in vivo applications to provide artificial barriers, for example, barriers to prevent tissue adhesion following surgery. For this application, the initiator polymer along with polymerizable material is applied to the surface of the tissue. The composition is then illuminated to initiate polymerization and formation of the barrier matrix. The polymeric matrix prevents other tissue from adhering to the coated tissue. In some procedures a polymeric matrix can be formed on the surface of a blood vessel to prevent blood factors or cells, such as platelets, from interacting with or adhering to the blood vessel wall. Both degradable and non-degradable macromer systems can be used for this purpose.
As stated above, in some instances, a pharmaceutical agent can be administered to the subject after receiving the encapsulated cells. The pharmaceutical agent can provoke a therapeutically useful cellular response from the encapsulated cells if needed. Other useful drugs that can be administered to subjects having encapsulated cells include antithrombogenic, anti-inflammatory, antimicrobial, antiproliferative, and anticancer compounds, as well as growth factors, morphogenic proteins, and the like.
The invention will now be demonstrated referring to the following non-limiting examples.
Table I.
EITC APTAC EITC
N 1r-CH2 N / CH2 N / CH2 NH NH NH
APTAC APTAC APTAC
(Compound I: APTAC-EITC-PEI Initiator Polymer)
As stated above, in some instances, a pharmaceutical agent can be administered to the subject after receiving the encapsulated cells. The pharmaceutical agent can provoke a therapeutically useful cellular response from the encapsulated cells if needed. Other useful drugs that can be administered to subjects having encapsulated cells include antithrombogenic, anti-inflammatory, antimicrobial, antiproliferative, and anticancer compounds, as well as growth factors, morphogenic proteins, and the like.
The invention will now be demonstrated referring to the following non-limiting examples.
Table I.
EITC APTAC EITC
N 1r-CH2 N / CH2 N / CH2 NH NH NH
APTAC APTAC APTAC
(Compound I: APTAC-EITC-PEI Initiator Polymer)
- 27 -0 \
x Z
(Compound II: PEG-triacrylate macromer) EXAMPLES
Example 1 Synthesis of APTAC-Polyethylenimine (APTAC-PEI) Polymer As starting material for the preparation of a photoinitiator polymer, a positively-charged polymer having a polyethylenimine backbone coupled to cationic quaternary ammonium groups was prepared.
Quaternary ammonium groups, in the form of (acrylamidopropyl)trimethyl-ammonium chloride molecules were coupled to a polyethylenimine polymer using the following procedure: Five grams of polyethylenimine (10,000 Mw;
Polysciences, Warrington, PA) were dissolved in 10 ml of deionized water to make a 50% PEI solution. To the 50% PEI solution was added 16 g of a 75% (3-acrylamidopropy1)- trimethylammonium chloride solution (APTAC; Simga-Aldrich Corp., St. Louis, MO). The mixture of PEI and APTAC was shaken overnight at 55 C. The resulting product was a viscous, amber-colored solution, which was stored in a sealed vial at room temperature.
Monitoring the vinyl protons of the APTAC molecule by NMR (Nuclear Magnetic Resonance) on a small scale reaction of equivalent concentrations used in the preparation of APTAC-PEI indicated the reaction was 99% complete at room temperature in 16 hours.
Using a 2.4:1 w/w ratio of APTAC to PEI (12 g APTAC to 5 g PEI
(10,000Da)) as described above, it was estimated that the final Mw of APTAC-PEI
x Z
(Compound II: PEG-triacrylate macromer) EXAMPLES
Example 1 Synthesis of APTAC-Polyethylenimine (APTAC-PEI) Polymer As starting material for the preparation of a photoinitiator polymer, a positively-charged polymer having a polyethylenimine backbone coupled to cationic quaternary ammonium groups was prepared.
Quaternary ammonium groups, in the form of (acrylamidopropyl)trimethyl-ammonium chloride molecules were coupled to a polyethylenimine polymer using the following procedure: Five grams of polyethylenimine (10,000 Mw;
Polysciences, Warrington, PA) were dissolved in 10 ml of deionized water to make a 50% PEI solution. To the 50% PEI solution was added 16 g of a 75% (3-acrylamidopropy1)- trimethylammonium chloride solution (APTAC; Simga-Aldrich Corp., St. Louis, MO). The mixture of PEI and APTAC was shaken overnight at 55 C. The resulting product was a viscous, amber-colored solution, which was stored in a sealed vial at room temperature.
Monitoring the vinyl protons of the APTAC molecule by NMR (Nuclear Magnetic Resonance) on a small scale reaction of equivalent concentrations used in the preparation of APTAC-PEI indicated the reaction was 99% complete at room temperature in 16 hours.
Using a 2.4:1 w/w ratio of APTAC to PEI (12 g APTAC to 5 g PEI
(10,000Da)) as described above, it was estimated that the final Mw of APTAC-PEI
- 28 -was approximately 3.4 times greater (34,000 Da) than the Mw of the starting PEI
polymer (10,000 Da).
Example 2 Synthesis of APTAC-EITC-Polyethylenimine (APTAC-EITC-PEI) Initiator Polymer The positively-charged APTAC-PEI polymer synthesized in Example 1 was used as starting material for the preparation of a photoinitiator polymer having pendent photoinitiator groups.
The APTAC-PEI polymer (200 1) as synthesized in Example 1 was dissolved in 5 ml of DMSO. Eosin-isothiocyanate (100 mg) (EITC; Helix Research, Springfield, OR) was dissolved in 45 ml DMSO to make a 2.2 mM EITC solution.
Solutions or reactions containing the EITC solution were subsequently performed in the dark or in light sealed containers. 5 ml of the APTAC-PEI/DMSO solution was mixed with 45 ml of the 2.2mM EITC/DMSO solution and mixed for 24 hours at room temperature.
After 24 hours unreacted EITC was removed via ultrafiltration using two Biomax filters (5,000 M, cutoff (MWC0); Millipore Co. Billerica, MA) using 2,000 mls of a 20% DMSO, 80% water solution as a wash. The next wash was performed with 2,000 mls of 50 mM ammonium carbonate instead of the DMSO/water solution also using two 5,000 MN cutoff Biomax filters. 231 mg of APTAC-EITC-PEI polymer product was recovered by lyophilization and stored protected from light at room temperature. The final weight of the APTAC-EITC-PEI initiator polymer product was approximately 42.5 IcDa.
A APTAC-EITC-PEI initiator polymer product can be represented by Compound Tin Table I.
Example 3 Preparation of APTAC-EITC-PEI Initiator Polymers of Various Molecular Weights Using a procedure similar to that described in Examples 1 and 2, APTAC-EITC-PEI initiator polymers having variations in both (a) molecular weights and (b) EITC content were prepared.
PEI polymers having Ms of 750,000 (750K) Da, 10,000 (10K) Da, 2,000 (2K) Da, and 800 Da were obtained from Polysciences, Warrington, PA. To prepare
polymer (10,000 Da).
Example 2 Synthesis of APTAC-EITC-Polyethylenimine (APTAC-EITC-PEI) Initiator Polymer The positively-charged APTAC-PEI polymer synthesized in Example 1 was used as starting material for the preparation of a photoinitiator polymer having pendent photoinitiator groups.
The APTAC-PEI polymer (200 1) as synthesized in Example 1 was dissolved in 5 ml of DMSO. Eosin-isothiocyanate (100 mg) (EITC; Helix Research, Springfield, OR) was dissolved in 45 ml DMSO to make a 2.2 mM EITC solution.
Solutions or reactions containing the EITC solution were subsequently performed in the dark or in light sealed containers. 5 ml of the APTAC-PEI/DMSO solution was mixed with 45 ml of the 2.2mM EITC/DMSO solution and mixed for 24 hours at room temperature.
After 24 hours unreacted EITC was removed via ultrafiltration using two Biomax filters (5,000 M, cutoff (MWC0); Millipore Co. Billerica, MA) using 2,000 mls of a 20% DMSO, 80% water solution as a wash. The next wash was performed with 2,000 mls of 50 mM ammonium carbonate instead of the DMSO/water solution also using two 5,000 MN cutoff Biomax filters. 231 mg of APTAC-EITC-PEI polymer product was recovered by lyophilization and stored protected from light at room temperature. The final weight of the APTAC-EITC-PEI initiator polymer product was approximately 42.5 IcDa.
A APTAC-EITC-PEI initiator polymer product can be represented by Compound Tin Table I.
Example 3 Preparation of APTAC-EITC-PEI Initiator Polymers of Various Molecular Weights Using a procedure similar to that described in Examples 1 and 2, APTAC-EITC-PEI initiator polymers having variations in both (a) molecular weights and (b) EITC content were prepared.
PEI polymers having Ms of 750,000 (750K) Da, 10,000 (10K) Da, 2,000 (2K) Da, and 800 Da were obtained from Polysciences, Warrington, PA. To prepare
-29 -PEI having 50% APTAC coupling, a 2.4:1 w/w ratio of APTAC to PEI for each different sized PEI polymer was used. In to prepare PEI having 20% APTAC
coupling, a 0.96:1 w/w ratio of APTAC to PEI for each different sized PEI
polymer was used. Reagents and reaction times as detailed in Example 1 were used for each of the preparations. Subsequently, preparations of APTAC-PEI polymers of the recited sizes were then coupled to EITC molecules using reagents and reaction times as detailed in Example 2. Specifically, each APTAC-PEI polymer preparation (200 111) was dissolved in 5 ml of DMSO and mixed with 45 ml of the 2.2mM
EITC/DMSO solution and then mixed for 24 hours at room temperature. The purification steps as detailed in Example 2 were performed for each of the samples and the yields of each preparation was comparable to that of the recovery using the 10,000 Mw PEI polymer of Examples 1 and 2.
According to the results it is calculated that the final Ms of the initiators at a 50% APTAC target loading will be as follows:
Starting Mw PEI (Da) Approximate ),PEI (Dal (a) 800 3400 (b) 2000 8500 (c) 10,000 42,500 (d) 750,000 3.2 X 106 Example 4 Preparation of APTAC-EITC-Dendrimer Initiator Polymers Using a procedure similar to that described in Examples 1 and 2, PEI-APTAC-dendrimer initiator polymers were prepared. An amine functional dendrimer with a molecular weight of 14,215 Da was used as a polymer backbone in place of the 10,000 Da PEI used in examples 1 & 2.
As a first step in the synthesis of the dendrimer initiator polymer, an intermediate APTAC-dendrimer was made. One gram of ethylenediamine-core poly(amidoamine) dendrimer (PAMAM dendrimer, Generation 4, FW 14,215 Da, 10 wt% in methanol; Sigma-Aldrich, St. Louis, MO) was placed in a flask along with 44.7 mg of a 75% APTAC solution (Sigma-Aldrich). The methanol was removed on a rotary evaporator to give a residue of 176 mg and the residue was
coupling, a 0.96:1 w/w ratio of APTAC to PEI for each different sized PEI
polymer was used. Reagents and reaction times as detailed in Example 1 were used for each of the preparations. Subsequently, preparations of APTAC-PEI polymers of the recited sizes were then coupled to EITC molecules using reagents and reaction times as detailed in Example 2. Specifically, each APTAC-PEI polymer preparation (200 111) was dissolved in 5 ml of DMSO and mixed with 45 ml of the 2.2mM
EITC/DMSO solution and then mixed for 24 hours at room temperature. The purification steps as detailed in Example 2 were performed for each of the samples and the yields of each preparation was comparable to that of the recovery using the 10,000 Mw PEI polymer of Examples 1 and 2.
According to the results it is calculated that the final Ms of the initiators at a 50% APTAC target loading will be as follows:
Starting Mw PEI (Da) Approximate ),PEI (Dal (a) 800 3400 (b) 2000 8500 (c) 10,000 42,500 (d) 750,000 3.2 X 106 Example 4 Preparation of APTAC-EITC-Dendrimer Initiator Polymers Using a procedure similar to that described in Examples 1 and 2, PEI-APTAC-dendrimer initiator polymers were prepared. An amine functional dendrimer with a molecular weight of 14,215 Da was used as a polymer backbone in place of the 10,000 Da PEI used in examples 1 & 2.
As a first step in the synthesis of the dendrimer initiator polymer, an intermediate APTAC-dendrimer was made. One gram of ethylenediamine-core poly(amidoamine) dendrimer (PAMAM dendrimer, Generation 4, FW 14,215 Da, 10 wt% in methanol; Sigma-Aldrich, St. Louis, MO) was placed in a flask along with 44.7 mg of a 75% APTAC solution (Sigma-Aldrich). The methanol was removed on a rotary evaporator to give a residue of 176 mg and the residue was
- 30 -heated in an oven at 37 C for 3.5 days. NMR analysis of the residue in deuterated methanol (CD30D) indicated the reaction was greater than 99% complete based on the vinyl protons of APTAC.
An APTAC-dendrimer/DMSO solution was prepared by dissolving 30mg of the APTAC-dendrimer intermediate in 5 ml of DMSO. An EITC/DMSO solution was prepared by dissolving 25 mg of eosin-isothiocyanate (EITC; Helix Research, Springfield, OR) in 300 microliters of DMSO. The dendrimer-APTAC/DMS0 solution was combined with the EITC/DMSO solution and mixed for 24 hours at room temperature. Solutions or reactions containing EITC were performed in light-protected containers (amber-colored vials).
After 24 hours unreacted EITC was removed via ultrafiltration using two Biomax filters (5,000 Mõ, cutoff (MWC0); Millipore Co. Billerica, MA) using 2 liters of a 20% DMSO, 80% water solution as a wash. The next wash was performed with 2 liters of 50 mM ammonium carbonate instead of the DMSO/water solution also using two 5,000 Mvõ cutoff Biomax filters. 47 mg of APTAC-EITC-dendrimer product was recovered by lyophilization and stored protected from light at room temperature.
Example 5 Preparation of a Trim ethylolpropane Ethoxylate (20/3 EO/OH) Triacrylate Macromer A PEG-based macromer was synthesized for use with the initiator polymers as detailed below.
Synthesis of the PEG-based macromer is illustrated in Figure 1.
Trimethylolpropane ethoxylate (PEG-triol; 100.0 g, 98.6 mmoles; Average M, ca.1,104; Cat. No. 41,617-7; Aldrich Chemical Company, Inc., Milwaukee, WI) was dissolved in 200 mls of toluene with stirring and refluxed for one hour. The PEG-triol solution was allowed to cool to approximately 80 C. At this time, 50 mg (0.403 mmoles) of 4-methoxyphenol (MEHQ; J.T. Baker, Phillipsburg, NJ), 42.7 g (0.592 moles) of acrylic acid (J.T. Baker, Phillipsburg, NJ), and 10 mls (0.188 moles) of sulfuric acid (Aldrich Chemical Company, Inc., Milwaukee, WI) were added with stirring to the reaction solution. The reaction solution was heated to reflux. The reaction was allowed to progress until about 6.0 mls of water was
An APTAC-dendrimer/DMSO solution was prepared by dissolving 30mg of the APTAC-dendrimer intermediate in 5 ml of DMSO. An EITC/DMSO solution was prepared by dissolving 25 mg of eosin-isothiocyanate (EITC; Helix Research, Springfield, OR) in 300 microliters of DMSO. The dendrimer-APTAC/DMS0 solution was combined with the EITC/DMSO solution and mixed for 24 hours at room temperature. Solutions or reactions containing EITC were performed in light-protected containers (amber-colored vials).
After 24 hours unreacted EITC was removed via ultrafiltration using two Biomax filters (5,000 Mõ, cutoff (MWC0); Millipore Co. Billerica, MA) using 2 liters of a 20% DMSO, 80% water solution as a wash. The next wash was performed with 2 liters of 50 mM ammonium carbonate instead of the DMSO/water solution also using two 5,000 Mvõ cutoff Biomax filters. 47 mg of APTAC-EITC-dendrimer product was recovered by lyophilization and stored protected from light at room temperature.
Example 5 Preparation of a Trim ethylolpropane Ethoxylate (20/3 EO/OH) Triacrylate Macromer A PEG-based macromer was synthesized for use with the initiator polymers as detailed below.
Synthesis of the PEG-based macromer is illustrated in Figure 1.
Trimethylolpropane ethoxylate (PEG-triol; 100.0 g, 98.6 mmoles; Average M, ca.1,104; Cat. No. 41,617-7; Aldrich Chemical Company, Inc., Milwaukee, WI) was dissolved in 200 mls of toluene with stirring and refluxed for one hour. The PEG-triol solution was allowed to cool to approximately 80 C. At this time, 50 mg (0.403 mmoles) of 4-methoxyphenol (MEHQ; J.T. Baker, Phillipsburg, NJ), 42.7 g (0.592 moles) of acrylic acid (J.T. Baker, Phillipsburg, NJ), and 10 mls (0.188 moles) of sulfuric acid (Aldrich Chemical Company, Inc., Milwaukee, WI) were added with stirring to the reaction solution. The reaction solution was heated to reflux. The reaction was allowed to progress until about 6.0 mls of water was
- 31 -produced and collected via a Dean & Stark receiver (approximately one hour).
The reaction mixture was allowed to cool to 50 C and poured into a solution of sodium bicarbonate (270 g in 2.5 liters of deionized water) with stirring. The organic layer was separated, washed with deionized water and dried over sodium sulfate. The PEG-triacrylate was isolated using a wiped film still (Pope Scientific, Inc., Saukville, WI).
A PEG-triacrylate macromer product is represented by Compound II in Table I.
Example 6 Cell Encapsulation Using APTAC-EITC-PEI Initiator Polymers The positively-charged initiator polymers as prepared in Examples 1, 2, and 3 are used as polymerization initiators to provide an encapsulating polymeric coating on the surface of cells. The cell encapsulation procedure includes the following steps: (i) contacting cells with a solution containing the APTAC-EITC-PEI polymers as prepared in examples 1-3; (ii) contacting cells with a solution containing the PEG-triacrylate macromer of Example 4; (iii) treating the cells in contact with the macromer and initiator with an argon laser light source; and (iv) washing with phosphate buffered saline (PBS). Following these steps the cells are inspected to determine the quality of coating around the cells (via microscopic examination) and the cell viability (trypan blue exclusion or propidiurn iodide staining).
The reaction mixture was allowed to cool to 50 C and poured into a solution of sodium bicarbonate (270 g in 2.5 liters of deionized water) with stirring. The organic layer was separated, washed with deionized water and dried over sodium sulfate. The PEG-triacrylate was isolated using a wiped film still (Pope Scientific, Inc., Saukville, WI).
A PEG-triacrylate macromer product is represented by Compound II in Table I.
Example 6 Cell Encapsulation Using APTAC-EITC-PEI Initiator Polymers The positively-charged initiator polymers as prepared in Examples 1, 2, and 3 are used as polymerization initiators to provide an encapsulating polymeric coating on the surface of cells. The cell encapsulation procedure includes the following steps: (i) contacting cells with a solution containing the APTAC-EITC-PEI polymers as prepared in examples 1-3; (ii) contacting cells with a solution containing the PEG-triacrylate macromer of Example 4; (iii) treating the cells in contact with the macromer and initiator with an argon laser light source; and (iv) washing with phosphate buffered saline (PBS). Following these steps the cells are inspected to determine the quality of coating around the cells (via microscopic examination) and the cell viability (trypan blue exclusion or propidiurn iodide staining).
Claims (46)
1. A method comprising the steps of:
(a) providing a surface selected from the group consisting of: a biological surface comprising the surface of cells, the surface of a group of cells, or the surface of tissue;
and a synthetic surface selected from plastics, ceramic, resins, polysaccharides, silicon, silica-based materials, glass, metals, films, gels, membranes, nylon, natural fibers, and polymers;(b) contacting the surface with a positively-charged initiator polymer comprising:
(i) an initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive-charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8;
(c) contacting the surface with a polymerizable material; and (d) activating the initiator group of the positively-charged initiator polymer to cause polymerization of the polymerizable material on at least a portion of the surface.
(a) providing a surface selected from the group consisting of: a biological surface comprising the surface of cells, the surface of a group of cells, or the surface of tissue;
and a synthetic surface selected from plastics, ceramic, resins, polysaccharides, silicon, silica-based materials, glass, metals, films, gels, membranes, nylon, natural fibers, and polymers;(b) contacting the surface with a positively-charged initiator polymer comprising:
(i) an initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive-charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8;
(c) contacting the surface with a polymerizable material; and (d) activating the initiator group of the positively-charged initiator polymer to cause polymerization of the polymerizable material on at least a portion of the surface.
2. The method of claim 1 wherein the positively-charged initiator polymer has a polymeric backbone that comprises nitrogen.
3. The method of claim 2 wherein polymeric backbone comprises a polyimine backbone.
4. The method of claim 3 wherein the polymeric backbone comprises polyethylenimine.
5. The method of claim 1 wherein the positively-charged initiator polymer has a polymeric backbone and the cationic portion comprises a cationic group pendent from the polymeric backbone.
6. The method of claim 5 wherein the cationic portion comprises a group selected from the group consisting of quaternary ammonium, quaternary phosphonium, and ternary sulfonium.
7. The method of claim 6 wherein the cationic portion comprises a quaternary ammonium group.
8. The method of claim 1 wherein the cationic portion provides a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 10.
9. The method of claim 8 wherein the cationic portion provides a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 12.
10. The method of claim 1 wherein the initiator group comprises a photoinitiator.
11. The method of claim 10 wherein the photoinitiator has an excitation wavelength of 350 nm or greater.
12. The method of claim 11 wherein the photoinitiator has an excitation wavelength of 500 nm or greater.
13. The method of claim 12 wherein the photoinitiator is selected from the group consisting of acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, and xanthine dyes.
14. The method of claim 1 wherein the positively-charged initiator polymer comprises at least five initiator groups.
15.
of less than 3.2 X 10 6 Da.
The method of claim 1 wherein the positively-charged initiator polymer has a M
w
of less than 3.2 X 10 6 Da.
The method of claim 1 wherein the positively-charged initiator polymer has a M
w
16. The method of claim 15 wherein the positively-charged initiator polymer has a M w of 250,000 Da or less.
17. The method of claim 16 wherein the positively-charged initiator polymer has a M w in the range of 8,500 to 250,000 Da.
18. The method of claim 17 wherein the positively-charged initiator polymer has a M w in the range of 8,500 to 100,000 Da.
19. The method of claim 1 wherein the positively-charged initiator polymer comprises up to 1000 monomeric units.
20. The method of claim 1 wherein the surface comprises a negatively charged surface.
21. The method of claim 1 wherein the surface comprises a biological surface.
22. The method of claim 21 wherein the surface comprises a cell.
23. The method of claim 22 further comprising the step of (e) introducing a coated cell or coated cells produced from steps (a) - (d) into a subject.
24. A positively-charged initiator polymer comprising: a polymeric backbone;
(a) a photoinitiator group coupled to the polymeric backbone, wherein the photoinitiator group is selected from the group consisting of acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, and xanthine dyes; and (b) a cationic portion providing a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8.
(a) a photoinitiator group coupled to the polymeric backbone, wherein the photoinitiator group is selected from the group consisting of acridine orange, camphorquinone, ethyl eosin, eosin Y, erythrosine, fluorescein, methylene green, methylene blue, phloxime, riboflavin, rose bengal, thionine, and xanthine dyes; and (b) a cationic portion providing a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8.
25. A kit for providing a polymeric coating to a selected from the group consisting of:
a biological surface comprising the surface of cells, the surface of a group of cells, or the surface of tissue; and a synthetic surface selected from plastics, ceramic, resins, polysaccharides, silicon, silica-based materials, glass, metals, films, gels, membranes, nylon, natural fibers, and polymers, the kit comprising:
(a) a positively-charged initiator polymer comprising:
(i) a polymerization initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8; and (b) a polymerizable material.
a biological surface comprising the surface of cells, the surface of a group of cells, or the surface of tissue; and a synthetic surface selected from plastics, ceramic, resins, polysaccharides, silicon, silica-based materials, glass, metals, films, gels, membranes, nylon, natural fibers, and polymers, the kit comprising:
(a) a positively-charged initiator polymer comprising:
(i) a polymerization initiator group, and (ii) a cationic portion, wherein the cationic portion provides a positive charge to the positively-charged initiator polymer in conditions having a pH up to, and including, pH 8; and (b) a polymerizable material.
26. One or more cells encapsulated with a polymeric matrix, wherein the polymeric matrix is formed by the method of claim 22.
27. The positively charged initiator polymer of claim 24 wherein the polymeric backbone comprises nitrogen.
28. The positively charged initiator polymer of claim 27 wherein the polymeric backbone comprises polyimine.
29. The positively charged initiator polymer of claim 28 wherein the polymeric backbone comprises polyethylenimine.
30. The positively charged initiator polymer of claim 24 wherein the cationic portion comprises a cationic group pendent from the polymeric backbone, the cationic group selected from the group consisting of quaternary ammonium, quaternary phosphonium, and ternary sulfonium.
31. The positively charged initiator polymer of claim 24 comprising at least five photoinitiator groups.
32. The positively charged initiator polymer of claim 30 which comprises monomeric units in the polymeric backbone, and 20% or more of the monomeric units are coupled to the cationic groups.
33. The positively charged initiator polymer of claim 32 wherein 50% or more of the monomeric units are coupled to the cationic groups.
34. The positively charged initiator of claim 30 wherein the positively-charged initiator polymer has a ratio of cationic groups:photoinitator groups of at least 1:1.
35. The positively charged initiator polymer of claim 34 wherein the positively-charged initiator polymer has a ratio of cationic groups:photoinitiator groups of at least 2.5:1.
36. The positively charged initiator polymer of claim 35 wherein the positively-charged initiator polymer has a ratio of cationic groups:photoinitiator groups of at least 5:1.
37. The kit of claim 25 wherein the positively charged initiator polymer has a polymeric backbone that comprises nitrogen.
38. The kit of claim 37 wherein the polymeric backbone comprises polyimine.
39. The kit of claim 38 wherein the polymeric backbone comprises polyethylenimine.
40. The kit of claim 25, wherein the cationic portion comprises a cationic group pendent from the polymeric backbone and selected from the group consisting of quaternary ammonium, quaternary phosphonium, and ternary sulfonium.
41. The kit of claim 37, wherein the initiator polymer comprises at least five polymerization initiator groups.
42. The kit of claim 40 wherein the initiator polymer comprises monomeric units in the polymeric backbone, and 20% or more of the monomeric units are coupled to the cationic groups.
43. The kit of claim 42 wherein 50% or more of the monomeric units in the initiator polymer are coupled to the cationic groups.
44. The kit of claim 40 wherein the initiator polymer has a ratio of cationic groups:initiator groups of at least 1:1.
45. The kit of claim 44 wherein the initiator polymer has a ratio of cationic groups:initator groups of at least 2.5:1.
46. The kit of claim 45 wherein the initiator polymer has a ratio of cationic groups:photoinitiator groups of at least 5:1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/412,081 | 2003-04-10 | ||
US10/412,081 US7585499B2 (en) | 2003-04-10 | 2003-04-10 | Method for encapsulation of cellular material using a charged initiator polymer |
PCT/US2004/007809 WO2004093846A2 (en) | 2003-04-10 | 2004-03-12 | Charged initiator polymers and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2520968A1 CA2520968A1 (en) | 2004-11-04 |
CA2520968C true CA2520968C (en) | 2013-05-07 |
Family
ID=33131146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2520968A Expired - Lifetime CA2520968C (en) | 2003-04-10 | 2004-03-12 | Charged initiator polymers and methods of use |
Country Status (5)
Country | Link |
---|---|
US (2) | US7585499B2 (en) |
EP (1) | EP1613292A2 (en) |
JP (1) | JP4847318B2 (en) |
CA (1) | CA2520968C (en) |
WO (1) | WO2004093846A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7585499B2 (en) * | 2003-04-10 | 2009-09-08 | Surmodics, Inc. | Method for encapsulation of cellular material using a charged initiator polymer |
US7820158B2 (en) * | 2003-04-10 | 2010-10-26 | Surmodics, Inc. | Ligand-coupled initiator polymers and methods of use |
US8617895B2 (en) * | 2004-09-23 | 2013-12-31 | Tripath Imaging, Inc. | Polycationic quaternary ammonium polymer coatings for immobilizing biological samples |
US8377461B2 (en) * | 2004-12-06 | 2013-02-19 | Surmodics, Inc. | Multifunctional medical articles |
CN101253259A (en) * | 2005-07-20 | 2008-08-27 | 苏尔莫迪克斯公司 | Polymer coated nanofibrillar structures and methods for cell maintenance and differentiation |
US20070154518A1 (en) * | 2005-12-29 | 2007-07-05 | Robert Falotico | Photoactive biocompatible coating composition |
US20080063627A1 (en) * | 2006-09-12 | 2008-03-13 | Surmodics, Inc. | Tissue graft materials containing biocompatible agent and methods of making and using same |
US20090022805A1 (en) * | 2007-06-28 | 2009-01-22 | Joram Slager | Polypeptide microparticles having sustained release characteristics, methods and uses |
JP2010540696A (en) * | 2007-09-25 | 2010-12-24 | サーモディクス,インコーポレイティド | Durable swellable hydrogel matrix and method |
US20090123519A1 (en) * | 2007-11-12 | 2009-05-14 | Surmodics, Inc. | Swellable hydrogel matrix and methods |
US9042954B2 (en) * | 2009-11-24 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte sensors comprising hydrogel membranes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908404A (en) * | 1988-08-22 | 1990-03-13 | Biopolymers, Inc. | Synthetic amino acid-and/or peptide-containing graft copolymers |
CA2022480C (en) | 1989-08-02 | 2001-02-27 | Gerald L. Mechanic | Process for cross-linking collagenous materials and resulting product |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
WO1993017669A1 (en) * | 1992-02-28 | 1993-09-16 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5858653A (en) * | 1997-09-30 | 1999-01-12 | Surmodics, Inc. | Reagent and method for attaching target molecules to a surface |
US6007833A (en) * | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
US6410044B1 (en) * | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
US6884778B2 (en) | 2000-04-14 | 2005-04-26 | William Marsh Rice University | Biocompatible macromers |
WO2004032881A2 (en) | 2002-10-11 | 2004-04-22 | Novocell, Inc. | Implantation of encapsulated biological materials for treating diseases |
US7820158B2 (en) * | 2003-04-10 | 2010-10-26 | Surmodics, Inc. | Ligand-coupled initiator polymers and methods of use |
US7585499B2 (en) * | 2003-04-10 | 2009-09-08 | Surmodics, Inc. | Method for encapsulation of cellular material using a charged initiator polymer |
-
2003
- 2003-04-10 US US10/412,081 patent/US7585499B2/en active Active
-
2004
- 2004-03-12 WO PCT/US2004/007809 patent/WO2004093846A2/en active Application Filing
- 2004-03-12 CA CA2520968A patent/CA2520968C/en not_active Expired - Lifetime
- 2004-03-12 JP JP2006507185A patent/JP4847318B2/en not_active Expired - Fee Related
- 2004-03-12 EP EP04720494A patent/EP1613292A2/en not_active Withdrawn
-
2009
- 2009-04-02 US US12/384,338 patent/US8143043B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20090317887A1 (en) | 2009-12-24 |
US20040202774A1 (en) | 2004-10-14 |
JP4847318B2 (en) | 2011-12-28 |
JP2006524680A (en) | 2006-11-02 |
EP1613292A2 (en) | 2006-01-11 |
US7585499B2 (en) | 2009-09-08 |
WO2004093846A2 (en) | 2004-11-04 |
US8143043B2 (en) | 2012-03-27 |
WO2004093846A3 (en) | 2005-01-20 |
CA2520968A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8143043B2 (en) | Encapsulated cells using positively-charged initiator polymer | |
AU744190B2 (en) | Crosslinkable macromers bearing initiator groups | |
US5834556A (en) | Graft copolymer of polycationic species and water-soluble polymers, and uses therefor | |
RU2451525C2 (en) | Biodegradable cationic polymers | |
EP1379133A2 (en) | Two-phase processing of thermosensitive polymers for use as biomaterials | |
US20110040057A1 (en) | Ligand-coupled initiator polymers and methods of use | |
US8202833B2 (en) | Composition containing biocompatible polymerization accelerator and polymerizable material | |
US8728520B2 (en) | Cross-linked alginate-polyalkylene glycol polymer coatings for encapsulation and methods of making the same | |
US20230365754A1 (en) | Cross-linkable allylamido polymers | |
Li et al. | Bioresponsive Hydrogels and Microgels | |
AU768179B2 (en) | Crosslinkable macromers bearing initiator groups | |
Gerges | Synthesis of new cross linked poly (amidoamine) s as potential scaffolds for tissue engineering, and structural investigation studies by MALDI TOF analysis | |
AU2002244322A1 (en) | Two-phase processing of thermosensitive polymers for use as biomaterials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |